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ABSTRACT
The host-microbiome interaction and the functions of microbial-derived
metabolites, including butyrate, are important in colonic health. Butyrate is the preferred
energy substrate in colonocytes and has multiple physiological functions in the colon. A
metabolic shift in colonocytes toward increased glucose utilization from butyrate
oxidation is associated with several critical genetic modifications in cancerous
colonocytes. Moreover, it has been suggested that the gut-microbiota composition is
influenced by environmental factors, such as diet and the host's physiological status.
Therefore, an understanding of the role of colonocyte metabolism toward impacting the
host-microbiota commensal relationship would be an important step in characterizing the
functional importance of how diet, microbiome, and the host interact in colonic
physiology.
This dissertation demonstrates that (1) colorectal cancer cells exhibit a metabolic
shift from butyrate oxidation toward glycolysis; (2) the key factor in the metabolic shift is
decreased pyruvate kinase M1 (PKM1), rather than increased pyruvate kinase M2
(PKM2); (3) an increase in HIF1⍺ through a reduction in pyruvate as a result of
decreased PKM1 is a critical mechanism that serves to repress butyrate oxidation in
colorectal cancer cells. Also, this dissertation defines the functional importance of
butyrate oxidation and explains that (1) a diminishment of short-chain acyl
dehydrogenase (SCAD) in a non-disease mouse model reduces butyrate oxidation in
colonocytes and instead uses energy from glycolysis as a compensatory mechanism; (2)
the reduction of butyrate oxidation in SCAD-deficient mice results in a large decrease in
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the butyrate-producing bacteria population, thus linking host cellular metabolism with
microbiome composition as it relates to the dietary metabolites or SCFAs; (3) these
SCAD-deficient mice fail to respond in a prebiotic manner to dietary fiber.
These findings begin to characterize the different roles of the PKM isoforms in
the cancerous colonocytes and show how these proteins change metabolism in a disease
model. Also, the results allude to how colonocyte metabolism affects the population of
gut microbiota in the gastrointestinal (GI) tract, which defines a significant relationship
between butyrate and SCFAs metabolism in the colonocyte and colonic gut microbiota
homeostasis.
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INTRODUCTION

Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading
mortal cancer (Siegel et al., 2020). The National Cancer Institute (NCI) estimates that 149,500
new cases of CRC arise, and about 52,980 individuals will succumb to this disease in the 2021
(Siegel, Miller, Fuchs, & Jemal, 2021). CRC development can take several years for an adenoma
to develop into invasive carcinoma. Carcinoma is defined when the tumor invades into the
muscular layer and thereby signifies metastasis. During this process to become a carcinoma, the
adenoma must acquire key genomic and metabolic modifications to promote tumor growth and
aggressive characteristics (Jasperson, Tuohy, Neklason, & Burt, 2010). In addition to genetic
contributions, modifiable lifestyle, dietary factors, and the composition of gut microbiota can
increase or decrease the risk of developing CRC (Keum & Giovannucci, 2019; S. H. Wong &
Yu, 2019).
Inter-individual variability is one of the important characteristics of the gut microbiota
due to environmental and genetic factors (Bibbò et al., 2016). Among environmental factors,
different diets affect the gut microbiota composition regulating the amount of SCFAs, including
acetate, propionate, and butyrate, produced by the fermentation of dietary fibers by resident
microbiota (De Almeida, de Camargo, Russo, & Amedei, 2019). A balanced gut microbiota
composition is important for colonic health in the host. Cellular processes, including metabolism,
development and maintenance of the immune system, and protection against pathogens, are
important in mediating colonic physiology (Aune et al., 2011; Guinane & Cotter, 2013;
Holscher, 2017). In contrast, disturbance of the gut microbiota composition is associated with the
development and progression of CRC and ulcerative colitis (Ni, Wu, Albenberg, & Tomov,
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2017; Zou, Fang, & Lee, 2018), thereby associating the gut microbiota with colonic diseases.
However, the factors leading to these microbial differences are not entirely clear.
Of the microbial-derived SCFAs, butyrate serves as the primary energy source for
colonocytes, while acetate and propionate are rapidly taken up and reach systemic circulation to
contribute to the overall energetic homeostasis (Donohoe et al., 2011; Roediger, 1982). In
addition to being an energetic substrate, butyrate has anti-cancer effects through the induction of
epigenetic modifications that alter the expression of genes involved in cell proliferation,
apoptosis, and differentiation. Butyrate has this action by inhibiting histone deacetylases and is
identified as an HDAC inhibitor (HDACi) (Davie, 2003). During the development of colorectal
cancer, cancerous colonocytes primarily utilize glucose and undergo high levels of glycolysis
(the Warburg effect) with relatively low levels of mitochondrial butyrate oxidation (Bultman,
2014; Vander Heiden, Cantley, & Thompson, 2009; Warburg, 1956). However, the impact of
this metabolic shift and the mechanisms that contribute to diminished butyrate oxidation is not
entirely clear.
Therefore, this dissertation starts with comprehensive information on CRC, the
significance of dietary fibers and gut microbiota in colon health, the role of butyrate in the
colonocytes, and how metabolic enzymes such as PKM mediate the metabolic shift in colorectal
cancer cells. Specifically, Chapter 2 demonstrates the role of pyruvate kinase M1 in the
metabolic changes of cancerous colonocytes. Continuing on this aspect of butyrate oxidation,
Chapter 3 addresses whether this oxidation of butyrate and other SCFAs in the colonocyte (and
other host cells) regulates the amounts of butyrate-producing bacteria, thereby providing other
outcomes of altered metabolism in the colonocyte.

2

CHAPTER 1
LITERATURE REVIEW
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1.1. Colorectal Cancer
Colorectal cancer (CRC) is the second most common cause of cancer death in the United
States, and the National Cancer Institute (NCI) estimates that CRC is the third most diagnosed
malignancy globally in the 2020 (Siegel et al., 2020). CRC development is a complex process
resulting from various etiological factors, both genetic and environmental.
Over the past several decades, recent studies have suggested the biological and molecular
characteristics of CRC while also elucidating the underpinnings that give rise to CRC
development. Significant progress has been made in understanding genetic and epigenetic
alterations in the CRC genome, which supports the genetic perspective of CRC. However, more
than 42% of all cases and deaths are associated with environmental and modifiable risk factors
such as smoking, high alcohol consumption, unhealthy diets, physical inactivity, and excess body
weight, many of which could be prevented by effective strategies (Islami et al., 2018). Therefore,
it represents the importance of modifiable factors in CRC development.
Understanding the associations between the modifiable risk factors and the pathology of
CRC is important in reducing CRC incidence and mortality. One of the major modifiable risk
factors is diet. The first part of this dissertation begins with the general background of CRC,
including genetic approaches to carcinogenesis and modifiable risk factors.

1.1.1. Development of CRC
Colorectal cancer (CRC) is a disease of developing a malignant neoplasm, often referred
to as an adenocarcinoma, derived from granular epithelial cells in the colon or rectum (Board,
2002). CRC is considered an important disease model to better understand general tumor
progression and metastasis because gradually changing phenotypes are associated with
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measurable genetic mutations (Yeatman & Chambers, 2003). CRC shows a variety of genomic
alterations from small-scale changes, such as deletions or point mutations, to large-scale
chromosomal rearrangements or copy number changes (T. M. Kim, Lee, & Chung, 2013). The
loss of genomic stability can drive the development of CRC by facilitating multiple tumorassociated mutations. Several studies combine the perspectives of genetics, epigenetics, and
signaling pathways to focus on developing colon tumors from a gene perspective (Dwyer,
Colombo, & Bozzi, 1989; Fearon, Hamilton, & Vogelstein, 1987; Hassold, Kumlin, Takaesu, &
Leppert, 1985).
Colonic crypts comprise the basic structure of the large intestine. These crypts consist of
a monolayer of epithelial cells with a very high cell turnover (van der Flier & Clevers, 2009).
The colonic crypt, the functional unit of the intestine, is comprised of stem cells, proliferating
cells, and differentiated cells, which all form a finger-like introversion structure into the
connective tissue (Munro, Wickremesekera, Peng, Tan, & Itinteang, 2018). The columnar stem
cells, located at the crypt base, migrate toward the lumen through proliferation and undergo
differentiation as they move up the crypt (van der Flier & Clevers, 2009). The development and
turnover of these stem cells are affected by the host genetic programs associated with Wnt,
Hedgehog, and Noggin signals (Humphries & Wright, 2008).
CRC arises in the epithelium layer of the colonic crypt (Kowalczyk et al., 2020).
Aberrant crypt foci (ACF) are the earliest manifestation of colorectal neoplasia in the epithelium.
ACF eventually form adenomatous polyps, although not always (Fodde, 2002). In this regard,
several studies have shown that additional mutations of tumor-suppressor genes and oncogenes
are required to develop into neoplasia that becomes cancerous (Markowitz & Bertagnolli, 2009).
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Three major pathways are involved in the development of CRC. These include adenomacarcinoma sequence, serrated pathway, and inflammatory pathway (Keum & Giovannucci,
2019). The adenoma-carcinoma sequence is the conventional pathway of CRC development
(Figure 1A). In this model, the gradual accumulation of genetic and epigenetic mutations
promotes the conversion of normal cells into a small adenoma, large adenoma, and finally to
cancer or carcinoma (Armaghany, Wilson, Chu, & Mills, 2012). Colorectal tumors develop from
benign to malignant over time by obtaining a series of mutations (Vogelstein et al., 2013). Bert
Vogelstein was the first to identify these series of mutations, which predispose benign tumors to
become adenocarcinomas. The Vogelgram represents four major genetic mutations in CRC
development: adenomatous polyposis coli (APC), K-Ras, SMAD2, and SMAD4, TP53. Figure 2
shows the associated signaling pathways and a gradual series of histological phenotype changes,
which provide a better understanding of genetic modification in the CRC development (Fodde,
2002; Vogelstein et al., 2013). The most common mutation in CRC initiation is the APC, a
tumor-suppressor gene, which functions as a gatekeeper (Kinzler & Vogelstein, 1997). As a
consequence of the APC mutation, Wnt/β-catenin signaling is inappropriately activated because
APC is an essential cytoplasmic protein that targets β-catenin for the destruction (Parker &
Neufeld, 2020). In the absence of functional APC, the accumulated β-catenin translocates to the
nucleus, where it stimulates the transcription of proto-oncogenes that promote cell cycle
progression, including the DNA-binding proteins of T-cell factor (TCF) family, which help in
the epithelial transition to adenoma (Bian, Dannappel, Wan, & Firestein, 2020). Together with
other genetic mutations such as KRAS oncogene, APC mutations are necessary for the transition
to a large adenoma. KRAS activates MAPK leading to increased proliferation and invasion.
Mutations in the PI3K/AKT pathways represent another way to promote cell survival (S. Jones et

6

al., 2008). The transforming growth factor-β (TGF-β) pathway phosphorylates the tumor
suppressor gene products SMAD2 and SMAD4, reducing apoptosis and promoting proliferation
(H. Li et al., 2019). Several studies have shown that mutations that occur in TGF-β, SMAD2, and
SMAD4 genes are increased and vital in promoting CRC progression (Jung, Staudacher, &
Beauchamp, 2017). TP53 is the other critical tumor-suppressor gene, whose gene product is
involved in CRC development. Acquired mutations in TP53 are widespread in malignant
colorectal tumors. The absence of p53 leads to loss of this DNA damage checkpoint during the
cell cycle after the G phase, which is followed by increased cell proliferation, reduced apoptosis,
and induced malignant transformation (X. L. Li, Zhou, Chen, & Chng, 2015). Therefore,
mutations of these proto-oncogenes and tumor-suppressor genes play a pivotal role in the
metastasis, metabolic modification, and progression of the CRC (Markowitz & Bertagnolli,
2009; Vogelstein et al., 2013). Most importantly, multiple mutations and events are required to
develop CRC. The order or sequence of these mutations is also important in this process.
The serrated pathway is an alternative pathway in CRC development through serrated
adenomas (Figure 1B). This model is explained by the development from normal cells to
hyperplastic polyps, sessile serrated adenoma, and then to CRC (Leggett & Whitehall, 2010).
Mutations in the proto-oncogene BRAF induce uncontrolled cell proliferation through activation
of MAPK pathways that result in the formation of hyperplastic polyps (Kedrin & Gala, 2015).
The inflammatory pathway is the other distinct carcinogenic pathway (Figure 1C). In this
model, carcinogenesis is developed from normal cells to indefinite dysplasia, low-grade
dysplasia, high-grade dysplasia, and to CRC (Itzkowitz & Yio, 2004). Unlike the conventional
adenomas or serrated adenomas pathways, dysplasia is frequently present in flat mucosa with
multifocality. Thus, high-definition endoscopy or chromoendoscopy are recommended for
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patients with IBD over the traditional white-light colonoscopy (Buchner & Lichtenstein, 2016).
The molecular events and timing are also distinct from the adenoma-carcinoma sequence (Keum
& Giovannucci, 2019). In the inflammatory pathway, mutations in TP53 and APC respectively
occur early and late in CRC development (Robles et al., 2016).
CRC is staged by the TNM classification and staging system, which confers accurate
prognostic information and proper treatment plans for CRC patients (Ueno et al., 2012). This
system assigns the stage of CRC with the characteristics of the primary tumor (T), lymph node
involvement (N), and degree of metastasis (M) (Weiser, 2018). Stage I – cancer has dispersed
to the submucosa and slightly invaded the muscle layer of the colon wall; Stage II – cancer has
spread throughout the colon wall and close to the organs but not to the lymph nodes; Stage III –
cancer has dispersed to regional lymph nodes, but not to other normal organs; and Stage IV –
cancer has spread through the blood and lymph circulation to distant organs (Ueno et al., 2012)

1.1.2. Screening and Diagnosis of CRC
Incidence and mortality rates of CRC have been declining for several decades because of
earlier diagnosis through screening and better treatment modalities. Especially, screening enables
removing precancerous lesions before malignant transformation or early detection and treatment
of CRC (Provenzale et al., 2020).
CRC screening can be divided into stool tests and structural examinations (Quintero et
al., 2012). As stool tests, fecal occult blood tests (FOBTs), fecal immunochemical tests (FITs),
and multitarget stool DNA testing (FIT-DNA) can be applied, and a positive result from either
test will lead to further screening, such as a sigmoidoscopy or a colonoscopy (Imperiale et al.,
2014). The FOBTs and FITs can detect precancerous lesions or cancer with small amounts of
8

blood in stool samples (Wieten et al., 2019). The FIT-DNA indicates molecular aberrations
associated with CRC biomarkers such as KRAS mutations and aberrant BMP3 and NDRG4
methylation (Imperiale et al., 2014). Also, another tool for CRC diagnosis involves the analysis
of molecular biomarkers such as microsatellite instability (MSI), chromosomal instability (CIN),
and the CpG island methylator phenotype (CIMP) analysis in fecal samples, which reflect the
mechanisms of malignant cells (Gonzalez-Pons & Cruz-Correa, 2015).
Structural examinations, including colonoscopy, computed tomography (CT), 18-fluorlabeled fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography
(CT), and magnetic resonance imaging (MRI), can be used for detailed CRC screening and
diagnosis (Quintero et al., 2012). Cross-sectional imaging studies show the exact stage of
preoperative colorectal cancer, which provides important information in determining patient
prognosis and optimized treatment strategies (Kijima et al., 2014). First, colonoscopy is
recommended as a primary screening tool due to its high sensitivity for early detection of CRC
and its ability to take biopsies and remove polyps (Dominitz et al., 2017). Several populationbased case-control studies have shown that colonoscopy screening significantly lowers CRC risk
(Brenner, Chang-Claude, Seiler, Rickert, & Hoffmeister, 2011; Brenner et al., 2010; Click,
Pinsky, Hickey, Doroudi, & Schoen, 2018). As such, it is now recommended to begin at age 45
by the American Cancer Society (Wolf et al., 2018). However, colonoscopy is an imperfect
screening because of the sessile serrated adenoma/polyps (SSA/Ps) (Rashtak, Rego, Sweetser, &
Sinicrope, 2017). SSA/Ps are difficult to visualize at colonoscopy because they are flat and have
adherent mucus that makes them easier to overlook than conventional adenomas (Pohl et al.,
2013). Second, CT colonography has been widely used as an alternative to endoscopy because of
its safety, clinical performance, and cost-effectiveness in CRC screening (Yee, Weinstein,
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Morgan, Alore, & Aslam, 2013). Although detecting SSA/Ps is difficult with colonoscopy, CT
colonography can detect SSA/Ps (D. H. Kim, Lubner, Cahoon, Pooler, & Pickhardt, 2018). CT
colonography allows visualizing SSA/Ps despite the flat formation using an oral tagging agent
that mixes with adherent mucus to highlight the flat lesion (D. H. Kim et al., 2016). CT identifies
the colon and mesenteric and mesocolic infiltration and extracolonic organs metastasis such as
liver, lung, and lymph nodes with high accuracy (Mainenti et al., 2006). The superior spatial
resolution of CT scan allows the creation of three-dimension (3D) reconstructions. It is possible
to detect polyps or tumors specifically with accurate quantification of the lesion size and
metastasis identification, which cannot be seen with the endoscope (Pickhardt et al., 2003;
Sosna, Kruskal, Bar-Ziv, Copel, & Sella, 2005). Third, FDG-PET/CT is a practical clinical
methodology for evaluating CRC patients for tumor imaging because the metabolic shift toward
glycolysis occurs in many cancers, including CRC (Maffione et al., 2020). This clinical
technique illustrates the characteristics of CRC as a metabolic disease characterized by reduced
butyrate oxidation and increased glucose uptake and utilization (R. E. Brown, Short, & Williams,
2018). The principle of FDG-PET/CT is to detect FDG, a highly accumulated non-metabolized
glucose form within CRC cells, compared to non-cancerous colonocytes. This elevated FDG
uptake is due to increased aerobic glycolysis in the CRC cells (Chalabi, Bassiouny, & El Sedek,
2020). Therefore, FDG-PET/CT can detect undetermined lesions suspected of recurrent diseases
and identify the metastatic status of the CRC (Heriot et al., 2004).

1.1.3. Risk Factors of CRC
The risk factors of CRC include the following: demographic characteristics (age)
(Brändstedt et al., 2012); medical conditions [family history, individual history with
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inflammatory bowel diseases (IBDs), familial adenomatous polyposis (FAP), and metabolic
diseases]; lifestyle-related factors (low-physical activity, smoking, and alcohol consumption);
and dietary factors (elevated consumption of red or processed meat, and low intake of vegetables
and fruits) (Bailey et al., 2015) (Figure 3).
Among these risk factors, IBDs and a history of CRC in first-degree relatives are
associated with a much higher risk of CRC. On the other hand, an increased body mass index
(BMI), red or processed meat intake, cigarette smoking, low physical activity, low vegetable and
fruit consumption were associated with a moderately increased risk of CRC (Tsoi et al., 2009).

1.1.3.1.

Age

According to the National Cancer Institute (NCI), CRC incidence and mortality rates
increase with age (Siegel et al., 2020). Even though over 50 years is an obvious risk factor for
CRC, the overall incidence and mortality rates in those populations have been decreasing in
recent years due to early screening and detection (Zauber et al., 2012). On the other hand, the
incidence of CRC has been rising in the population under the age of 50 over the last several
decades due to low physical activity and Westernized diet patterns (S. G. Patel & Ahnen, 2018).
Following this trend, screening for CRC in average-risk patients (no predisposing conditions or
family history) is recommended at 45 years rather than 50 years by the American Cancer Society
(Wolf et al., 2018).
The gastrointestinal microbiome may be one factor impacting age-associated CRC
development. The trillions of microbes inhabiting the gastric intestinal tract comprise complex
communities, which significantly change across a lifetime through age, diet, environment, and
disease (Heintz & Mair, 2014; Kumar, Babaei, Ji, & Nielsen, 2016). As we age, the increased
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rate of gram-negative bacteria and the secretion of lipopolysaccharide (LPS) induce
inflammation in the gut (Schiffrin, Morley, Donnet-Hughes, & Guigoz, 2010). Also, the gut
microbiome modulates diverse signaling pathways, such as promoting inflammation and
oncogenesis (Murphy, Dias, & Thuret, 2014). Accordingly, the microbial alterations (dysbiosis)
in the gut during aging can be linked to intestinal permeability and clinically relevant conditions,
including IBDs (J. Choi, Hur, & Hong, 2018).

1.1.3.2.

Gender

Many researchers have suggested that men have higher CRC incidence and mortality
rates than women, even though the impact of gender on CRC incidence and mortality still needs
to be studied more (Brenner, Hoffmeister, & Haug, 2008; Matanoski, Tao, Almon, Adade, &
Davies-Cole, 2006). This increased susceptibility of men to developing CRC might relate to a
combination of multiple factors such as gender-related behavioral and biological causes (Cook,
McGlynn, Devesa, Freedman, & Anderson, 2011).
Compared to women, men usually are heavier smokers (Chang et al., 2014), consume
more alcohol (Schütze et al., 2011), and generally have worse dietary patterns (Churuangsuk,
Lean, & Combet, 2020; Imamura et al., 2015), which are all CRC risk factors, than women. The
anthropometric variables such as increasing quartiles of weight, hip and waist circumference,
BMI, and waist-hip ratio (WHR) could also be why men have higher rates of CRC incidence
than women (Brändstedt et al., 2012). Especially, men have a more outstanding excess intraabdominal adipose tissue accumulation, which is visceral fat, than women, and it could be
associated with an increased risk of CRC development (Tchernof & Després, 2013). Several
epidemiological studies have also reported that the anthropometric variables, the risk factors of
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CRC incidence, are significantly higher in men than women (Johnson et al., 2013; Moghaddam,
Woodward, & Huxley, 2007).
From a genetic perspective, the differences in genetic factors and hormones between men
and women have been suggested as rationales for gender-related differences in the colonic
carcinomas (Press et al., 2008). Both estrogen-β and androgen receptors and sex steroid hormone
receptors are expressed in the colon (Catalano et al., 2000; Fiorelli, Picariello, Martineti, Tonelli,
& Brandi, 1999) interacting with epidermal growth factor receptor (EGFR), a gene widely
expressed in the colonic tissue (Bonaccorsi et al., 2004; Levin, 2003). Increased EGFR
expression is related to poor prognosis and increased risk of invasion and metastasis in the CRC
(Press et al., 2008). Among two functional polymorphisms of EGFR, the variant HER-1 497K
observed in some females has been shown to attenuate ligand binding, decrease the expression of
proto-oncogenes, diminish tyrosine kinase activation, and reduce the growth stimulation (Moriai,
Kobrin, Hope, Speck, & Korc, 1994). Thus, these polymorphic variants of EGFR could represent
a rationale for gender-dependent differences in CRC development.

1.1.3.3.

Family History

The risk of CRC in a lifetime is significantly increased when individuals have a CRC
family history (Jasperson et al., 2010). About 20% of CRC cases occur among patients with a
family history of this disease (Clinton, Giovannucci, & Hursting, 2020). A meta-analysis of
observational studies showed that the risk of CRC is increased up to 2.24 times for individuals
with at least one affected first-degree relative (parents, siblings, and children) and up to 3.97
times for those with at least two affected first-degree relatives. Also, the degree of association
increased further when relatives were diagnosed with CRC before the age of 50 (Butterworth,
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Higgins, & Pharoah, 2006). Since the early onset of CRC is mainly caused by genetic alteration,
a reasonable explanation of the strong association between family history and CRC can be
attributed to inherited genetic patterns (Haggar & Boushey, 2009). In connection with inherited
genes, shared environmental factors, or a combination of these also contributes to CRC
development (Slattery, Edwards, Ma, & Friedman, 2000).

1.1.3.4.

Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis (FAP) is an inherited syndrome characterized by the
formation of hundreds to thousands of adenomas in the colorectum (Vasen et al., 2008). FAP
patients account for < 1% of all CRC cases (Bülow, 2003), and almost all FAP diagnostic
patients develop CRC without initial treatment at an early stage (Cruz-Correa & Giardiello,
2003). FAP is caused by APC gene mutation or bi-allelic MUTYH gene mutation (Al-Tassan et
al., 2002; Nielsen et al., 2007). The APC gene mutation is inherited in a way by an autosomal
dominant manner (Bisgaard, Fenger, Bülow, Niebuhr, & Mohr, 1994). The MUTYH gene
mutation is inherited in an autosomal recessive manner (Al-Tassan et al., 2002). Most FAP
patients with gene mutations develop hundreds of colorectal adenomas in childhood and
adolescence. Without surgical intervention, CRC will inevitably develop when the average age is
40-50 years old (Knudsen, Bisgaard, & Bülow, 2003). Therefore, regular surveillance of FAP
patients can reduce CRC and CRC-associated mortality (Vasen et al., 2008).

1.1.3.5.

Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Diseases (IBDs), including ulcerative colitis (UC) and Crohn’s
disease, are considered a critical risk factor for CRC development (Haggar & Boushey, 2009).
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The tissue samples from IBDs-related colitis patients demonstrated the increased expression of
nitric oxygen synthase (NOS) and reactive oxygen species (ROS) (Hofseth et al., 2003; Xavier &
Podolsky, 2007). This oxidative stress might lead to developing graded dysplasia that could
convert into colitis-associated CRC (Bye, Nguyen, Parker, Jairath, & East, 2017). Also, as the
IBD patients grow older with an increased duration of chronic inflammation and more prolonged
exposure to immunosuppression, the risk of CRC development increases (Axelrad, Lichtiger, &
Yajnik, 2016). Therefore, patients diagnosed with IBDs are recommended to have regular CRC
screening as early detection and treatment of IBDs can reduce its progression to CRC (E. R. Kim
& Chang, 2014).

1.1.3.6.

Metabolic Disease: Obesity and Diabetes

The development of CRC is strongly associated with obesity, which is supported by
epidemiological studies utilizing various anthropometric measures such as body mass index
(BMI) and waist circumference (WC) (Calle & Kaaks, 2004; Dong et al., 2017; Renehan, Tyson,
Egger, Heller, & Zwahlen, 2008). BMI can reflect overall body adiposity, and WC represents
abdominal adiposity (Keum & Giovannucci, 2019). Several epidemiological studies have shown
that WC is a more significant risk factor for CRC than BMI, which suggests that abdominal
adiposity, independent of overall body adiposity, is associated with an increased risk of CRC
compared to the BMI (Moore et al., 2004; Song et al., 2016). Abdominal fat is divided into
visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). VAT increases the
production of pro-inflammatory cytokines such as TNF-⍺ and reduces the production of the
insulin-sensitizing hormone adiponectin (Samaras, Botelho, Chisholm, & Lord, 2010), which
also promotes the recruitment and penetration of immune cells such as macrophages as
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compared to SAT (Bruun, Lihn, Pedersen, & Richelsen, 2005). Together these phenomena result
in insulin resistance and a chronic inflammatory state (Ouchi, Parker, Lugus, & Walsh, 2011)
that promotes tumor progression by altering the microenvironment (J. Park, Morley, Kim, Clegg,
& Scherer, 2014).
Type II diabetes has been correlated with CRC development (Flood, Strayer, Schairer, &
Schatzkin, 2010). Insulin resistance and hyperinsulinemia increase the free insulin-like growth
factor 1 (IGF-1), which is a causal factor for CRC development because it stimulates cell
proliferation and reduces apoptosis (Calle & Kaaks, 2004; Deng, Gui, Zhao, Wang, & Shen,
2012). Since diabetes and obesity are linked together, it is not easy to separate the individual
contributions of these conditions regarding the development of CRC.

1.1.3.7.

Sedentary Lifestyle and Physical Activity

A sedentary lifestyle and lack of physical activity are modifiable risk factors that may
contribute to the development of the CRC (Rezende et al., 2018). CRC development is decreased
by 24% when individuals participate in regular physical activity (Wolin, Yan, Colditz, & Lee,
2009). The American Cancer Society (ACS) also recommends at least 75-150 min of vigorous
exercise, 150-300 min of moderate-intensity exercise, or an equivalent combination in a week for
the CRC prevention (Rock et al., 2020). Physical activity might attenuate CRC incidence through
elevated gut motility, reducing intestinal transit time, enhanced insulin sensitivity, increased
metabolic efficiency, decreased inflammation, and improved immune system function (Haggar &
Boushey, 2009; Ruiz-Casado et al., 2017; Wolin et al., 2009). The effects of physical activity on
reducing CRC incidence might also be affected by visceral adipose tissue (VAT) loss
(Giovannucci & Martínez, 1996).
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1.1.3.8.

Smoking

Many studies have shown that smoking is one of the risk factors for lung cancer and CRC
(Haggar & Boushey, 2009; P. Patel & De, 2016; S. G. Patel & Ahnen, 2018; Tsoi et al., 2009). A
mixture of compounds in cigarette smoke can reach the colorectal mucosa through direct
ingestion or the circulatory system, thereby causing genetic and epigenetic aberration
(Giovannucci & Martínez, 1996). Tsoi et al. showed a 20% increased risk of CRC in current
smokers compared to never smokers (Tsoi et al., 2009). Liang et al. showed a 50% greater risk in
60 pack-smokers in a year, and this percentage lowers as the smoking initiation age goes up
(Liang, Chen, & Giovannucci, 2009). Moreover, a prospective study found that smoking
cessation for at least 10 years reduced CRC risk by about 50% compared to current smokers
(Nishihara et al., 2013). Several genome-wide methylation studies have suggested that epigenetic
alterations appear to be a significant contributor to smoking-induced CRC development, as
extensive changes in DNA methylation patterns have been found in smokers compared to nonsmokers (Figueiredo et al., 2015; Zeilinger et al., 2013). The effect of smoking on CRC
development can also be explained by carcinogens such as polycyclic aromatic hydrocarbons
(PAH) in tobacco, which form DNA adducts that promote irreversible DNA lesions, resulting in
tumor formation (Botteri, Iodice, Raimondi, Maisonneuve, & Lowenfels, 2008; Giovannucci &
Martínez, 1996).

1.1.3.9.

Alcohol Consumption

Alcohol consumption is associated with increased CRC incidence, in part, due to the
function of acetaldehyde, which is a known carcinogen in the human (Haggar & Boushey, 2009).
In a meta-analysis of 14 cohort studies, even light drinking (less than 1 alcoholic drink per day)
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significantly increased CRC risk compared to no or occasional alcohol consumption (Y. J. Choi,
Myung, & Lee, 2018). Orally ingested alcohol reaches the colonocyte through blood circulation
and diffuses into the colon lumen (Salaspuro, 1997). In the lumen, microbial alcohol
dehydrogenase metabolizes ethanol into toxic acetaldehyde, which enters the colonic epithelial
cells, causing damage to the mucosal membrane and enhancing the proliferation of regenerative
cells (Seitz & Stickel, 2007). The acetaldehyde is metabolized by microbial or colonic mucosal
acetaldehyde dehydrogenase (ALDH) to the acetate (Salaspuro, 1997). Non-metabolized
acetaldehyde may function as a carcinogen in the colon by causing DNA damage and inhibiting
DNA repair systems (Haggar & Boushey, 2009).

1.1.3.10. Dietary Factors
Dietary patterns could be divided into two groups. A “healthy” pattern, related to lower
CRC risk, is characterized by high intakes of fruits and vegetables, whole grains, fish or other
seafood, nuts or legumes, and low-fat milk or products. In contrast, the “unhealthy” pattern,
associated with higher CRC risk, is characterized by high intakes of red and processed meat,
refined grain, and sugar-sweetened beverages and desserts (Tabung, Brown, & Fung, 2017).
Red and processed meat could directly contribute to CRC incidence (Chan et al., 2011).
A meta-analysis of prospective studies showed that every 100g increase in red and processed
meat intake per day elevated CRC risk by 12% (A. R. Vieira et al., 2017). The effect of red and
processed meat on CRC development may be caused by carcinogenic compounds such as heme
iron in red meat, N-nitroso compounds in processed meat, and secondary bile acids or ionized
fatty acids from fats in the meats (Bastide, Pierre, & Corpet, 2011; Cascella et al., 2018). The
high cooking temperature and prolonged cooking time of meats can also produce carcinogenic
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compounds such as heterocyclic amines and polycyclic aromatic hydrocarbons (Gamage,
Dissabandara, Lam, & Gopalan, 2018; Helmus, Thompson, Zelenskiy, Tucker, & Li, 2013).
As a healthy diet pattern, high consumption of dietary fiber has been postulated to reduce
the risk of CRC (Aune et al., 2011). Mechanistically, indigestible fiber reduces colorectal
epithelium’s exposure to carcinogens by increasing the feces bulk and decreasing the transit time
(Holscher, 2017). The interaction between soluble fiber and the gut microbiota is also proposed
to reduce CRC risk. Soluble fiber, which has reached the colonic lumen, is fermented by the gut
microbiota into short-chain fatty acids, including acetate, propionate, and butyrate (Zeng,
Lazarova, & Bordonaro, 2014). In several in vitro studies with human intestinal cell lines,
butyrate increased the growth of normal colonocytes as a primary energy source; however, it
slowed proliferation and promoted apoptosis of cancerous colonocytes as an HDAC inhibitor.
Butyrate also significantly downregulated numerous pro-inflammatory pathways such as nuclear
factor kappa beta (NF-kB), interferon-gamma (IFN-γ), toll-like receptor 2 (TLR2), and tumor
necrosis factor-alpha (TNF-⍺) (Donohoe, Curry, & Bultman, 2013; Elce et al., 2017; Zeng,
Taussig, Cheng, Johnson, & Hakkak, 2017). Numerous epidemiological studies have come to
mixed or controversial results regarding the effect of dietary fiber on the CRC development
(Kunzmann et al., 2015; Y. Park et al., 2005; Song et al., 2018).

1.2. Dietary Fiber and Gut Microbiota in the Colon
Dietary fibers (DFs) have been considered an important factor in decreasing CRC risk, as
described in section 1. Many researchers have recently focused more on the relationship between
DFs, the gut microbiota, and the host. Gut microbiota helps regulate metabolic and immunologic
functions in the host through continuous communication with the host, which plays a crucial role
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in the gut health (Finlay et al. 2019; Goldsmith JR 2014). Section 2 describes a general
introduction to DFs and the gut microbiota in the colon and their role in CRC development.

1.2.1. Dietary Fiber
Dietary fibers (DFs) are defined as “carbohydrate polymers with at least three monomeric
units, neither digested nor absorbed in the small intestine” by the Codex Alimentarius
Commission (J. M. Jones, 2014). Various classification criteria describe DFs due to the
heterogeneous characterization of origin, physicochemical characteristics, and chemical
properties (Holscher, 2017). Understanding these multiple properties is very important because
each factor can affect microbial fermentation. Table 1 shows four different clinically meaningful
dietary fiber categories.
Regarding origin criteria, plant-based DFs can be derived from diverse sources such as
fruits, vegetables, grains, nuts, and legumes. Also, the fibers from different types of plants all
have different chemical compositions and physicochemical properties (Müller, Canfora, &
Blaak, 2018). For instance, apple contains pectin, while banana can be a source of inulin-type
fructans and resistant starch. Various DFs from plant-rich diets support gut microbiota
complexes to produce more SCFAs for the host (Titgemeyer, Bourquin, Fahey, & Garleb, 1991).
Chemical and physicochemical characteristics of DFs, including solubility, viscosity, and
fermentability, can affect the role of the gut microbiota in colonic health and provide benefits to
the host. DFs can also be divided into four clinically meaningful categories (Müller et al., 2018)
(Table1). Although insoluble DFs such as cellulose, fruit fiber, and wheat bran are not soluble in
water and resist fermentation by gut microbiota, they still provide laxative benefits by increasing
gut transit rate (Titgemeyer et al., 1991). In contrast, soluble, non-viscous fibers such as inulin,
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resistant starch, resistant maltodextrin, polydextrose, and oligosaccharides are readily fermented
by gut microbiota (Holscher, 2017). These soluble and non-viscous DFs naturally found in the
diets of wheat, artichokes, asparagus, agave, banana, garlic, onion, and leek (Moshfegh, Friday,
Goldman, & Ahuja, 1999). ß-glucan and pectin, which have high solubility, viscosity, and
fermentability, are naturally found in barley and oats (ß-glucan) and apple (pectin) (Schieber,
Stintzing, & Carle, 2001). Psyllium is a non-fermentable fiber that is also highly soluble and
viscous, which provides unique health benefits, including lowering blood cholesterol, improving
glycemic control, and weight loss (McRorie, 2015).

1.2.2. Prebiotics
Most prebiotics can be classified as DFs, but not all fibers can be classified as prebiotics
(Slavin, 2013). Gibson and Roberfroid introduced the concept of prebiotics, and they defined
them as “nondigestible food ingredients that beneficially affect the host by selectively
stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and
thus improving host health” in 1995 (G. R. Gibson & Roberfroid, 1995). In 2004, the definition
of prebiotics was updated with three scientific demonstrations: 1) resistance to gastric acidity,
hydrolysis by mammalian enzymes, and gastrointestinal absorption; 2) fermented by gut
microbiota; 3) selectively stimulate the growth and/or activity of intestinal bacteria potentially
associated with health and well-being (G. R. Gibson, Probert, Loo, Rastall, & Roberfroid, 2004).
Also, in 2010, as molecular analysis methods developed, the prebiotics definition was revised to
“a selectively fermented ingredient that allows specific changes, both in the composition and/or
activity of the gastrointestinal microbiota that confers benefits” (Glenn R. Gibson et al., 2010).
Prebiotics can be found naturally in asparagus, Jerusalem artichoke, chicory, garlic, leek, onion,
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oat, soybean, and wheat (Moshfegh et al., 1999). Several studies have suggested that
oligofructose and inulin, resistant starch (RS), and lactulose satisfy all criteria of the recent
definition of prebiotics, including the stimulation of the beneficial bacterial genus
Bifidobacterium (Costabile et al., 2010).
The beneficial effects of prebiotics consist of reducing potential pathogenic bacterial
subpopulations, improving host immunity by strengthening gut barriers, and increasing SCFAs
production (Slavin, 2013). Prebiotics inulin in asparagus, garlic, and onions promote the growth
of Bifidobacteria while limiting the growth of potentially pathogenic bacteria E. coli,
Salmonella, and Listeria (Chong, 2014; G. R. Gibson & Roberfroid, 1995). The consumption of
the prebiotics oligofructose showed benefits through decreased antibiotic use in infants and
reduced the possibility of illness, including diarrhea or respiratory events (Saavedra & Tschernia,
2002). Polydextrose consumption also resulted in a beneficial effect by lowering Bacteroides and
increasing Lactobacilli and Bifidobacteria in a dose-dependent manner (Hengst, Ptok, Roessler,
Fechner, & Jahreis, 2009; Jie et al., 2000). Wheat dextrin decreased the amount of Clostridium
perfringens and increased Lactobacilli and Bifidobacteria (Lefranc-Millot et al., 2012). Several
epidemiological studies have also shown that banana and maize-based whole-grain breakfast
cereal increase the bifidobacterial genus of the gut microbiota (Carvalho-Wells et al., 2010;
Mitsou et al., 2011).

1.2.3. Gut Microbiota
The trillions of microbes that inhabit the gastrointestinal (GI) tract comprise a diverse and
complex ecosystem dynamic through different life stages. The composition of this microbial
ecosystem is impacted by diets, environmental circumstances, health status, and age (Heintz &

22

Mair, 2014; Kumar et al., 2016). The environment of the colon is satisfactory for gut microbiota
growth because of readily available nutrients, favorable pH, and the slow transit time
(Cummings & Macfarlane, 1991). Through the NIH Human Microbiome Project, the
composition and functions of gut microbiota have been identified and characterized as to the
influence in shaping human health and diseases (Peterson et al., 2009).
The type of diets can change the composition of gut microbiota, which could affect the
relative amount of different SCFAs produced through microbial fermentation (Tan et al., 2014).
Soluble DFs and prebiotics, including pectin, guar gum, fructo-oligomers, inulin, and resistant
starch, are the primary substrates for the fermentation by colonic bacteria (Slavin, 2013). These
substrates can be fermented into various end-products, including gases (H2, CO2, and CH4) and
SCFAs such as acetate, propionate, and butyrate (Holmes, Li, Athanasiou, Ashrafian, &
Nicholson, 2011). The end-products contribute to many physiological processes, including
promoting nutrient digestion and metabolism, maintaining epithelial barrier homeostasis, and
regulating immune-cell development to support the host health (Holmes et al., 2011; Macfarlane
& Macfarlane, 2012). Figure 4 shows the physiological benefits of the metabolites derived from
bacterial fermentation and their underlying mechanisms (Macfarlane & Macfarlane, 2012;
Slavin, 2013).
The gut microbiome composition is different among healthy individuals, which signifies
various capacities to digest DFs. The level of metabolites by microbiota fermentation of DFs
could be different due to the different individual microbiomes (Huttenhower et al., 2012).
Firmicutes and Bacteroidetes account for more than 90% of the microbiome in the gut, and the
rest are Actinobacteria, Verrucomicrobia, Fusobacteria, and Proteobacteria (Kuo, 2013). The
diversity in microbial communities is changed significantly during the entire life span and is

23

impacted by dietary patterns, environmental circumstances, and drug administration (Costello,
Stagaman, Dethlefsen, Bohannan, & Relman, 2012). Under a healthy homeostatic condition, a
diverse gut microbiota regulates mucous production and antimicrobial peptides (AMPs) secretion
and increases the gut barrier integrity by producing SCFAs (Nagpal et al., 2018).
Reduced gut microbiota diversity under dysbiotic conditions may have various systemic
immune and inflammatory effects (Macpherson & Harris, 2004). For example, the decreased
ratio of Firmicutes/Bacteroidetes can cause Inflammatory Bowel Diseases (IBDs), which are
related to the increased production of pro-inflammatory cytokines by pathogenic bacteria (AlAsmakh & Hedin, 2015). On the other hand, the increased ratio of Firmicutes/Bacteroidetes can
lead to obesity due to Firmicutes having a better capacity to produce SCFAs, and indirectly
metabolizing carbohydrates and lipids (Stojanov, Berlec, & Štrukelj, 2020).
Diets also significantly affect gut microbiota composition and the production of
microbial-derived metabolites (Scott, Gratz, Sheridan, Flint, & Duncan, 2013). The presence of
high-DFs, prebiotics, and polyphenol contributes to balanced microbiota formation by increasing
Bifidobacteria, Lactobacillus, and Firmicutes (Sokol et al., 2008; Takahashi et al., 2016; W.
Wang et al., 2014). On the other hand, low-DFs, low-polyphenol, and high-fat diets increase the
gram-negative bacterial population producing toxic metabolites causing disease development
(Holmes et al., 2011; Kuo, 2013). Polyphenol-derived metabolites and SCFAs production from
high-DFs diets and/or polyphenols are associated with less inflammation and inflammatory
disease development (Carding, Verbeke, Vipond, Corfe, & Owen, 2015). Therefore, gut
microbiota homeostasis is an important factor in maintaining a healthy colonic environment
while also reducing the risk of IBDs and CRC.
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1.2.4. Gut Microbiota in IBDs and CRC
Gut microbiota has several significant functions to contribute to the host colon health.
The microbiota interacts with the host immune system to protect against pathogen invasion and
colonization. It also provides essential nutrients and energy, such as amino acids and short-chain
fatty acids (SCFAs) (Carding et al., 2015). Various environmental factors, including diets,
toxins, and pathogens, can alter the composition of gut microbiota and lead to disease
development such as IBDs and CRC resulting from the alterations of metabolite composition
derived from microbial fermentation (Holmes et al., 2011; Kinross, Darzi, & Nicholson, 2011)
(Figure 5).
The characteristic of the gut microbiota in IBDs patients is the loss of diversity in
individuals with a lower abundance of Firmicutes and a higher percentage of Proteobacteria
(Sokol et al., 2008). In particular, the concentration of luminal butyrate is decreased due to the
reduction of butyrate-producing bacteria such as Clostridium lavalense, Faecalibacterium
prausnitzii, Ruminococcus torques, and Roseburia inulinivorans (Becker, Neurath, & Wirtz,
2015; Frank et al., 2007), which increases the levels of C-reactive protein, reflecting a high
inflammatory status (Takahashi et al., 2016). Several studies have shown that mucous-associated
microbiota in IBDs patients is rich in E. coli without any difference between inflammatory and
non-inflammatory areas (Olaisen et al., 2021; Vidal et al., 2015). Adhesive E. coli has been
observed in more than 30% of these patients, which can invade epithelial cells, replicate in
epithelial cells and macrophages, and produce inflammatory reactions in which IL-1β
degradation through NLRP3-inflammasome activation (Rolhion & Darfeuille-Michaud, 2007).
In addition, in Crohn’s disease patients, mucosal-related fungi such as Basidiomycota and
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Ascomycota phyla, Cystofilobasidiaceae family, and Candida glabrata genus were increased,
which can contribute to mucosal inflammation (Liguori et al., 2016).
Regarding CRC development, the production of carcinogenic metabolites derived from
pathogenic bacteria, including Streptococcus spp., Escherichia Coli, Fusobacterium nucleatum,
and Bacteroides, provide a possible causative mechanism (Sobhani et al., 2011). The pathogenic
bacteria, such as Clostridium difficile, Fusobacterium spp., and Campylobacter spp., promote the
pro-inflammatory reactions of mucosal tissues by producing reactive oxygen species (ROSs) and
subsequently contribute to the development of CRC by causing DNA damage (Louis & Flint,
2009). Desulfovibrio Vulgaris is one of the sulfur-reducing bacteria and increases with higher
meat consumption. The increased level of Desulfovibrio Vulgaris produces carcinogenic
compounds hydrogen sulfide and causes DNA damage, mucosal inflammation, and cell death,
resulting in CRC development (O'Keefe, 2008).
IBDs patients have a higher risk of developing CRC with a worse prognosis than sporadic
CRC. However, the pathological mechanisms contributing to the transition from IBDs to CRC
remain unclear (Gasaly, Hermoso, & Gotteland, 2021). Wong, S. H. et al. suggest that the gut
microbiota play a role in the pathological mechanisms contributing to IBDs and CRC. This study
supported the importance of the gut microbiota in CRC development by administering fecal
samples of CRC patients to germ-free and conventional mice. The fecal samples of CRC patients
increased polyp numbers, intestinal dysplasia and proliferation, inflammation markers, and the
colonic Th1 and Th17 cells in the experimental animals compared to those treated with non-CRC
individuals' fecal samples (S. H. Wong et al., 2017).
Therefore, it is very important to understand the function of gut microbiota and the
potential carcinogenic metabolites produced by these bacteria in preventing CRC development
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(Sears & Garrett, 2014). In particular, diet interventions, including DFs, prebiotics, and
probiotics, help prevent CRC development or reduce the size and number of progressing tumors
by improving the diversity and community of gut microbiota and promoting SCFAs production
(Geier, Butler, & Howarth, 2006). In conclusion, it is expected that ways to target specific
pathogenic bacteria or improve the overall gut microbiota composition through probiotics or
prebiotics will be an effective strategy in CRC prevention.

1.3. Butyrate
Butyrate is one of three major short-chain fatty acids (SCFAs) derived from the bacterial
fermentation of DFs (Hamer et al., 2008). Butyrate has been shown to affect the growth and
differentiation of colonocytes in vitro and has beneficial effects in vivo on CRC prevention
(McNabney & Henagan, 2017). Butyrate is a primary energy source for non-cancerous
colonocytes, where it is oxidized in the mitochondria as a fatty acid. This role as an energetic
source promotes colonocyte proliferation (Fleming, Fitch, DeVries, Liu, & Kight, 1991;
Roediger, 1982). In contrast, butyrate is not fully metabolized by mitochondrial oxidation in
cancerous colonocytes due to the Warburg effect (Donohoe, Collins, et al., 2012). As a result of
this diminished oxidation, butyrate accumulates in the nucleus. It may function as a histone
deacetylase (HDAC) inhibitor to regulate gene expression, thereby inhibiting cell proliferation
and promoting apoptosis (Archer, Meng, Shei, & Hodin, 1998; Chopin, Toillon, Jouy, & Le
Bourhis, 2002). This is called the “Butyrate Paradox” (Comalada et al., 2006) (Figure 6). In
addition, butyrate has many roles in colonocytes, such as reducing oxidative stress, modulating
the immune system, inducing cell differentiation. Butyrate also systemically decreases adiposity
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and improves insulin sensitivity. Section 3 will provide detailed information on the synthesis of
butyrate, its metabolism, and its various functions in the cell depending on cellular phenotype.

1.3.1. Butyrate Synthesis and Metabolism in Colonocytes
Butyrate is synthesized by several gut bacteria species belonging to the phylum
Firmicutes, particularly Eubacterium rectale and Roseburia spp. within Clostridial cluster XIVa,
and Clostridium leptum and Facalibacterium prausnitzii within Clostridial cluster IV (Louis &
Flint, 2009, 2017). Two acetyl-CoA molecules form Butyryl-CoA in a process resembling
reversed β-oxidation (Duncan, Louis, Thomson, & Flint, 2009). After that, two final enzymes are
utilized alternatively to convert butyryl-CoA to butyrate (Figure 7). The butyryl-CoA: acetate
CoA-transferase is used in most gut microbiota, while the butyrate kinase is found in a few
strains from the butyrate-producing bacteria (Louis & Flint, 2009). The gut microbiota species
using the butyryl-CoA: acetate CoA-transferase pathway are Eubacterium rectale, Roeseburia
spp, Coprococcus catus, Anaerostipes spp., and Faecalibacterium prausnitizii. Alternatively,
Coprococcus eutactus and Coprocuccus comes produce butyrate with the butyrate kinase
pathway (Duncan et al., 2009; Louis & Flint, 2009).
In addition to these two pathways, butyrate can also be synthesized using other
metabolites through cross-feeding (De Vuyst & Leroy, 2011). Bifidobacteria cannot synthesize
butyrate because it does not have the required enzymes used in the butyrate production (Klijn,
Mercenier, & Arigoni, 2005). However, the degradation of inulin or oligofructose by
Bifidobacteria can be utilized to produce acetate, which is then cross-fed to butyrate-producing
bacteria, so the bifidogenic effect is accompanied by a butyrogenic result (Moens, Weckx, & De
Vuyst, 2016). Also, the lactate and acetate, produced by Biciodobacteria and Lactobacilli
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through metabolizing fructans as an energy source, are used by other butyrate-producing
bacteria, including Faecalibacterium, Eubacterium, and Roseburia to produce butyrate (Gwen
Falony & De Vuyst, 2009; Schwiertz, 2016). Thus, both acetate and lactate can be used as
substrates to produce butyrate via cross-feeding.
Butyrate production is affected by several factors, including an individual’s different gut
microbiota composition, intestinal pH, source of DFs, and other bacteria-derived metabolites and
environmental factors (Flint, Duncan, Scott, & Louis, 2015). As mentioned above, an
individual’s gut microbiota composition affects butyrate synthesis because other metabolites
such as acetate and lactate, which are produced by different microbial species, can be cross-fed
for the butyrate synthesis (Pryde, Duncan, Hold, Stewart, & Flint, 2002). Also, appropriate
intestinal pH is essential to maintain butyrate-producing bacteria and the butyrate levels in the
colon (Duncan et al., 2009). An in vitro fermentation study utilizing human fecal samples found
that more acidic conditions promoted the growth of butyrate-producing bacteria Firmicutes while
showing a decreased amount of the acid-sensitive Bacteroides spp. (Walker, Duncan, McWilliam
Leitch, Child, & Flint, 2005). Lastly, while most fermentable DFs produce SCFAs, resistant
starches and fructo-oligosaccharides are considered the most effective butyrogenic DFs
(Guilloteau et al., 2010).
The physiological level of butyrate in the human colon is from 10 to 30 mM, and 95% of
butyrate is rapidly absorbed into and utilized by colonic epithelial cells (Louis, Hold, & Flint,
2014). Butyrate synthesized by the gut microbiota is absorbed by nonionic diffusion across the
colonocyte, or it can be transported inside the colonocyte via monocarboxylate transport protein1
(MCT1). MCT1 is coupled to a transmembrane H+-gradient and sodium-coupled
monocarboxylate transporter 1 (SMCT1), a Na+-coupled co-transporter (Counillon, Bouret,
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Marchiq, & Pouysségur, 2016; Cresci, Thangaraju, Mellinger, Liu, & Ganapathy, 2010; Tan et
al., 2014). After transport into the cell, butyrate undergoes mitochondrial β-oxidation to produce
acetyl-CoA, which then enters the TCA cycle and is used for ATP production (Hagland &
Søreide, 2015). In the mitochondria, short-chain acyl-CoA dehydrogenase (SCAD) catalyzes the
first step of the β-oxidation (Astbury & Corfe, 2012). SCAD deficiency by deletion and/or
mutation reduces butyrate catabolism by up to 60% and increases butyrate excretion, resulting in
inefficient butyrate metabolism as an energy source (Augenlicht et al., 1999).

1.3.2. The Function of Butyrate in Colonocytes
The primary role of butyrate in non-cancerous colonocytes is as an energy substrate
(Roediger, 1982). The importance of this role was reflected in one study, where the loss of
butyrate and the microbiome resulted in an energy deficiency status that was included a
significant reduction in enzymes that function in the TCA cycle and an overall lower ATP level
in isolated colonocytes. This energy deficiency ultimately caused germ-free (GF) colonocytes to
undergo autophagy, a self-degradation process of cellular components to maintain energy
homeostasis (C. He & Klionsky, 2009; Z. Yang & Klionsky, 2009). Recolonization of butyrateproducing bacteria in GF mice and treatment of GF colonocytes with butyrate rescued the defects
in mitochondrial respiration and reduced autophagy (Donohoe et al., 2011). This study outlined
the importance of host-microbe interaction about colonocyte energy metabolism. Donohoe et al.
(2012) showed that the proximal colon of GF mice was found to have lower ATP levels than
other tissues suggesting that butyrate is utilized as a primary energy source for colonocytes. It
was also found that butyrate is a key factor in recovering mitochondrial oxidation and cell-cycle
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defects by being used as a major energy source in GF mice colonocytes (Donohoe, Wali,
Brylawski, & Bultman, 2012).
Butyrate is also an important substrate for lipogenesis through the production of citrate
via the TCA cycle and conversion to the cytoplasmic acetyl-CoA (Gee, Blackburn, & Johnson,
1983). In the mitochondria, citrate is formed from butyrate-derived acetyl-CoA, combined with
Oxaloacetate (OAA). The generated citrate is exported to the cytosol and converted into OAA
and acetyl-CoA to provide the initial backbone for the de novo fatty acid synthesis (Bultman,
2014).
Another primary function of butyrate is its role as a histone deacetylase inhibitor
(HDACi). By inhibiting the recruitment of HDACs to the promoters of many genes (Davie,
2003; Macfarlane & Macfarlane, 2012), butyrate relax the wrapped chromatin around histones
and increases the accessibility of transcription factors to DNA, which changes the expression of
subsequent genes (Encarnação, Abrantes, Pires, & Botelho, 2015). The effect of butyrate as
HDACi slows the cell cycle and reduces cell proliferation by targeting the p21 cyclin-dependent
kinase inhibitor and stimulating apoptosis by increasing the expression of proapoptotic BAX and
FAS genes (Hamer et al., 2008; Sengupta, Muir, & Gibson, 2006).
Butyrate also affects histone acetylation by providing acetyl groups, the substrate in
acetyltransferase reactions. Recent studies have shown that the role of butyrate in histone
acetylation through this mechanism is more complicated than previously described (Bultman,
2014; Donohoe et al., 2013). Two distinct mechanisms, ACL-dependent and/or ACLindependent, increase histone acetylation by butyrate (Figure 8A). These mechanisms are
selected by the butyrate concentration in the colonocytes (Donohoe, Collins, et al., 2012). At a
lower butyrate concentration (0.5-1mM), it stimulates HATs activity through an ACL-dependent
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mechanism, where it is metabolized oxidatively, producing acetyl-CoA via ACL. Although
acetyl-CoA in the cytosol is utilized for lipogenesis, acetyl-CoA in the nucleus serves as a
cofactor for histone acetyltransferases (HATs) (Wellen et al., 2009). Thus, in the ACL-dependent
mechanism, the generated acetyl-CoA is utilized for the HAT cofactor, promotes histone
acetylation, and has been shown to increase cell proliferation and decrease apoptosis (Donohoe,
Collins, et al., 2012). However, when oxidation is saturated at a high butyrate concentration (25mM), the unmetabolized butyrate can accumulate in the nucleus and increase histone
acetylation through the ACL-independent mechanism or presumably as an HDACi (Bultman,
2014) (Figure 8B). This butyrate dose-dependent shift in epigenetic mechanisms is significant in
regulating cell proliferation and apoptosis in the colonocytes (Donohoe, Collins, et al., 2012).
Therefore, the selection between HATs and HDACi, the epigenetic mechanisms of butyrate,
depends on the butyrate concentration of colonocytes (Donohoe et al., 2013).
Since both ACL-dependent/independent mechanisms are butyrate concentrationdependent, understanding how butyrate levels fluctuate and are different throughout the colonic
crypt is significant. Butyrate concentration exists in a gradient along the colonic crypt-villus axis,
with a lower level around the stem/progenitor cells and a higher level around the upper side of
the crypt due to the structure (Donohoe, Collins, et al., 2012). The colonic crypt is a protective
structure to the stem cells through utilizing butyrate by colonocytes at the upper part (Kaiko et
al., 2016) (Figure 8A). The upper part of the colonic crypt is composed of apoptotic epithelium
for luminal exfoliation, while the crypt base is filled with proliferative cells (L. C. Yu, Wang,
Wei, & Ni, 2012). As mentioned earlier, the high butyrate concentration in the colonocytes
around the upper part of the colonic lumen enters the nucleus and functions as HDACi leading to
apoptosis, which exfoliates colonocytes into the lumen (Bultman, 2014). In contrast, at the
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bottom of the crypts with a low butyrate concentration (0.5mM), butyrate is metabolized by βoxidation, producing acetyl-CoA, which serves as a cofactor for histone acetyltransferases
(HATs) in the nucleus (Wellen et al., 2009). With an ACL-dependent mechanism, the generated
acetyl-CoA is utilized for HATs cofactor and promotes histone acetylation, increasing cell
proliferation and decreasing apoptosis (Donohoe, Collins, et al., 2012). Therefore, the
homeostasis of the colonic crypt and the colonocytes can be maintained by these butyrate
epigenetic mechanisms (ACL-dependent and/or ACL-independent) that regulate the gene
expression (Bultman, 2014; Donohoe, Collins, et al., 2012) (Figure 8).
Butyrate has anti-inflammatory activity through several mechanisms (Leonel & AlvarezLeite, 2012). The effect of butyrate to regulate inflammation is exerted by inhibiting HDAC or
stimulating G-protein-coupled receptors (GPRs) present in epithelial and immune cells,
suppressing the activation of nuclear factor B (NF-kB) and increasing PPAR- ɣ genes
transcription (Gasaly et al., 2021; Segain et al., 2000). These mechanisms include the reduction
of pro-inflammatory cytokines such as IL-6, IL-8, TNF-⍺, and INF-ɣ, the induction of antiinflammatory cytokines such as IL-10 and TNF-β, the increase of metalloproteinases and nitric
oxide synthase (iNOS), and the diminishment of lymphocyte activation and proliferation (Cao et
al., 2011; Hudcovic et al., 2012; E. L. Vieira et al., 2012; Vinolo et al., 2011).
The other effects of butyrate in regulating biological mechanisms come from interactions
with GPRs, which function on the cell surface to activate cAMP and phosphatidylinositol
signaling pathways that may modulate several effects (Louis et al., 2014). Butyrate is a primary
ligand for GPR41, GPR43, and GPR109A, expressed along with the entire GI tract (Guilloteau et
al., 2010). GPR41 and GPR43 are primarily found on the surface of the intestinal endocrine Lcells, where they stimulate the release of intestinal peptide YY (PYY) and glucagon-like peptide
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1 (GLP-1) (Kasubuchi, Hasegawa, Hiramatsu, Ichimura, & Kimura, 2015). PYY and GLP-1 are
involved in energy homeostasis by controlling food intake and insulin secretion (Larraufie et al.,
2018). GPR41 and GPR43 deficient mice showed a reduction of butyrate-induced PYY and
GLP1 (Hong et al., 2005; Tolhurst et al., 2012). Therefore, the stimulation of GPR41 and GPR43
by butyrate has beneficial effects on energy metabolism through PYY and GLP-1 secretion in the
gut (Kasubuchi et al., 2015). GPR109A is expressed in the apical membrane (towards the lumen)
of the colonocyte, adipose tissue, and immune cells (Ganapathy, Thangaraju, Prasad, Martin, &
Singh, 2013). The expression of GPR109A is decreased in cancerous colonocytes, which is
associated with altering DNA methylation in these cells. Also, NF-kB activation by LPS in noncancerous and cancerous colonocytes is blocked by GPR109A/butyrate, thereby suggesting this
receptor is important in mediating the anti-inflammatory effects of the butyrate (Thangaraju et
al., 2009).

1.4. A Metabolic Shift in Cancer cells
Cancer cells metabolize glucose with rapid glycolysis producing lactate, even under
abundant oxygen conditions. Non-cancerous cells metabolize glucose with low rates of
glycolysis followed by mitochondrial oxidation through the tricarboxylic acid (TCA) cycle (Hsu
& Sabatini, 2008; Vander Heiden et al., 2009; Warburg, 1956). Although the Warburg Effect is a
less efficient way to produce ATP compared to mitochondrial oxidative phosphorylation, the
abnormal rate of glycolysis can counteract the low efficiency as well as it is a crucial metabolic
adaptation in cancer cells to obtain biosynthetic intermediates such as nucleotides, fatty acids,
membrane lipids, and proteins for rapid cancer cell growth and proliferation (Hsu & Sabatini,
2008; Warburg, 1956) (Figure 9). This metabolic shift in cancer cells is stimulated by cell
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signaling caused by the status of the microenvironment, activation of oncogenes, and/or
inactivation of tumor-suppressor genes related to the metabolic activity (Table 2) (Ward &
Thompson, 2012).

1.4.1. Hypoxia-Inducible Transcription Factor-1 (HIF1)
Tumor growth restricts blood supply and creates a hypoxic condition that stabilizes the
hypoxia-inducible transcription factor-1(HIF-1), promoting transcriptional programs that help
the cell resist hypoxic stress (Kaelin & Ratcliffe, 2008). HIF-1 is a heterodimeric structure
composed of two subunits, HIF-1⍺ and HIF-1β (G. L. Wang, Jiang, Rue, & Semenza, 1995).
HIF-1⍺ is an oxygen-sensitive subunit and stabilizes under hypoxic conditions, while HIF-1β is
stably expressed (Masoud & Li, 2015). Thus, HIF-1⍺ plays an important role in the adaptation
response of cancer cells to hypoxic conditions and shifts the primary metabolism of cancer cells
from oxidative phosphorylation toward glycolysis by regulating more than 60 target genes,
which are involved in two characteristics of tumors: glycolysis and angiogenesis (Semenza,
2003).
HIF-1 increases the expression of glucose transporters (GLUTs), induces the expression
of enzymes involved in the glycolysis pathway, and decreases mitochondrial oxidation
(Semenza, 2010). Pyruvate, the final product of glycolysis, is an essential metabolic control point
because it can be converted into lactic acid by lactate dehydrogenase (LDHA) or acetyl-CoA by
pyruvate dehydrogenase (PDH) to enter the TCA cycle. HIF-1 activates the expression of
pyruvate dehydrogenase kinase 1 (PDK1), thus inactivating PDH via phosphorylation of the E1
subunit (J. W. Kim, Tchernyshyov, Semenza, & Dang, 2006). As a result of activation of PDK1
by HIF-1, pyruvate is shunted away from the mitochondrial oxidative phosphorylation. This shift
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is an adaptive response to hypoxic conditions (Papandreou, Cairns, Fontana, Lim, & Denko,
2006). HIF-1⍺ induces the expression of LDHA, converting pyruvate to lactate, and
monocarboxylate transporter 4 (MCT4), transporting lactate out of the cell (Ullah, Davies, &
Halestrap, 2006). Here, produced lactate in hypoxic cancer cells is taken up by non-hypoxic cells
to be utilized as an energy source (Sonveaux et al., 2008). Also, HIF-1 increases the expression
of BNIP3 protein, which selectively triggers mitochondrial autophagy to reduce ROS generation
under hypoxic conditions and once again protects the cancer cells (Zhang et al., 2008). In
addition, HIF-1 induces proto-oncogene Ras expression to promote vascular endothelial growth
factor (VEGF), a pro-angiogenic factor, and stimulates new vascular development to supply
oxygen for tumor cell growth (Conway, Collen, & Carmeliet, 2001).
Induced proto-oncogenes and suppressed tumor suppressor genes can also stimulate
metabolic changes. The mutation of a proto-oncogene Ras promotes glycolysis by stabilizing
HIF-1 (C. V. Dang & Semenza, 1999). Another oncogenic transcription factor, MYC, promotes
glycolysis and lactate production by increasing LDHA expression (Mazure, Chen, Yeh,
Laderoute, & Giaccia, 1996). In addition, loss of tumor suppressor transcription factor p53
stimulates the transcription of hexokinase promoter to induce glycolysis, simultaneously
reducing the expression of synthesis of cytochrome c oxidase (SCO2) protein, thereby
decreasing the function of mitochondrial respiration (Matoba et al., 2006).

1.4.2. Pyruvate Kinase M1/2 (PKM1/2)
Proliferating cancer cells require cancer-specific energy metabolism, Warburg Effect,
which needs ATP and biosynthetic building blocks (Vander Heiden et al., 2009). As one of the
ways to enhance biosynthetic ability, increased glycolysis has been considered as a hallmark of
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cancer cells (Hanahan & Weinberg, 2011). Pyruvate kinase is a rate-limiting glycolytic enzyme
that catalyzes the last step in glycolysis, converting phosphoenolpyruvate (PEP) to pyruvate
producing ATP (Cruz et al., 2017). PKM1 and PKM2 are alternatively spliced isoforms from the
PKM gene (Takenaka et al., 1991). Importantly, each isoform has a different expression pattern,
functions, enzyme kinetics (Sun, Zhao, Zhou, & Hu, 2012). PKM1 is generally expressed in
differentiated tissues such as the brain, muscle, and colon, where it tends to oxidative
metabolism. In contrast, PKM2 is expressed in proliferating cells, including colorectal cancer
cells, where it enhances the aerobic glycolysis (Christofk, Vander Heiden, Harris, et al., 2008;
Christofk, Vander Heiden, Wu, Asara, & Cantley, 2008).
PKM1 and PKM2 are alternatively spliced isoforms from the Pyruvate Kinase M gene,
containing exon 9 or exon 10, respectively (Israelsen & Vander Heiden, 2015; Takenaka et al.,
1991). Several splicing factors, such as heterogeneous nuclear ribonucleoproteins family
(hnRNP), serine/arginine-rich splicing factor (SRSF), and RNA-binding motif 4 (RBM4),
regulate the alternative splicing of the PKM gene (Alquraishi et al., 2019). Among the hnRNP
family, polypyrimidine tract binding protein 1 (PTBP1) promotes the elimination of exon 9 to
produce PKM2 (Clower et al., 2010). The serine/arginine-rich splicing factor 3 (SRSF3)
encourages the production of PKM2 by increasing the addition of exon 10 (Kuranaga et al.,
2018). In contrast, the RNA-binding motif 4 (RBM4) splicing factor inhibits splicing factor
PTBP1, thereby reducing the expression of PKM2 (Su, Hung, Hung, & Tarn, 2017).
While PKM1 continually maintains an active R-state tetramer conformation, PKM2 has
four different enzymatic states, which are an inactive monomer, a nearly inactive dimer, an
inactive T-state tetramer, and an active R-state tetramer (N. Wong, Ojo, Yan, & Tang, 2015).
PKM2 is allosterically activated by the glycolytic intermediate fructose-bisphosphate (FBP) or
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fructose 2,6-bisphosphate (F-2,6-BP), while PKM1 is not regulated by FBP (Valentini et al.,
2000). Moreover, the active tetramer formation of PKM2 is allosterically activated by serine
binding to each monomer (Chaneton et al., 2012). On the other hand, PKM2 is allosterically
inactivated by ATP, oxalate, alanine, and phenylalanine (Morgan et al., 2013).
The post-translational modification also can modify PKM2 enzymatic activity, including
phosphorylation, acetylation, and methylation (Prakasam, Iqbal, Bamezai, & Mazurek, 2018).
First, phosphorylation of PKM2 is one of the major post-translational modifications, which
inhibits PKM2 enzymatic properties and enhances nuclear translocation of the PKM2
(Alquraishi et al., 2019). The phosphorylation of PKM2 at tyrosine-105 changes the formation of
PKM2 from tetramer to dimer states that inhibits catalytic activity and induces aerobic glycolysis
(Warburg Effect) (Hitosugi et al., 2009). In addition, the phosphorylation of PKM2 at threonine454 and serine-37 promotes aerobic glycolysis by increasing the PKM2 nuclear translocation
(W. Yang et al., 2012; Z. Yu et al., 2016). The phosphorylation of PKM2 decreases catalytic
activity by reducing mitochondrial function and induces tumorigenesis. In contrast, the
dephosphorylation of PKM2 appears to reduce cell growth and invasiveness in cancerous cells
(Lori et al., 2018). Second, the acetylation of PKM2 at lysine-433 encourages nuclear
translocation of PKM2 and enhances its contributions toward tumorigenesis, while the
deacetylation of PKM2 by SIRT6 causes exporting PKM2 from the nucleus and decreases cancer
cell proliferation and migration (Bhardwaj & Das, 2016; Lv et al., 2013). On the other hand, coactivator-associated arginine methyltransferase 1 (CARM1) induces the methylation of PKM2 at
arginine-455/477 and promotes enzymatic activity by PKM2 tetramerization, which may have
therapeutic properties (Abeywardana et al., 2018).

38

Several researchers have found that cancer cells, including cancerous colonocytes, prefer
the tumor-specific form of pyruvate kinase M2 (PKM2) expression among PKM1/2 isoforms and
are associated with a poor prognosis in patients (Alquraishi et al., 2019; Christofk, Vander
Heiden, Wu, et al., 2008). The increase in PKM2 has been coined as a potential colorectal cancer
biomarker (Christofk, Vander Heiden, Wu, et al., 2008; Radeva et al., 2008; Yeh et al., 2008).
The main advantage of PKM2 in cancer cells is that it is possible to convert glycolytic
intermediates upstream of PEP can be shunted into other synthetic processes, such as increasing
the incorporation of glucose carbon into the lipids synthesis (Christofk, Vander Heiden, Harris,
et al., 2008; Christofk, Vander Heiden, Wu, et al., 2008).
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Table 1. Four Clinically Meaningful Dietary Fiber Categories
Clinically Meaningful Category

Health Benefits

Insoluble

Laxative Effect

Soluble/Non-viscous/Readily
Fermented

Rapidly Fermented
Considered a Prebiotic

Soluble/Viscous/Readily Fermented

Lowering Cholesterol
Improved Glycemic Control

Soluble/Viscous/Non-fermented

Lowering Cholesterol
Improved Glycemic Control
Stool Normalization
Weight Loss

Representative Fibers
Cellulose
Corn bran
Fruit fiber
Rice bran
Wheat bran
Wheat dextrin
Inulin
Oligosaccharides
⍺-Cyclodextrin
Resistant maltodextrins
Polydextrose
Resistant starch
Soy fiber
β-glucan (oats and barley)
Guar gum
Glucomannan (Konjac)
Pectins
Gum arabic
Psyllium

Dietary fibers are categorized regarding their clinically meaningful properties and
physicochemical characteristics, including solubility, viscosity, and fermentability.
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Table 2. The molecular alterations in cancer cells causing the metabolic shift toward
glycolysis
Mechanisms

↑ HIF1⍺

Gene Expression

↑ c-MYC

Results
↑ Glucose Transporter Expression
↑ Glycolytic Enzymes Expression
→ PDK and LDHA

↑ Aerobic Glycolysis & ↓ β-oxidation
↑ Glucose Transporter Expression
↑ Glycolytic Enzymes Expression
→ PDK and LDHA

↑ Aerobic Glycolysis & ↓ β-oxidation
↓ p53

↑ Glycolytic Enzymes Expression
↓ β-oxidation Enzymes Expression
→ cytochrome C oxidase 2

↑ Glucose Transporter Expression
↑ Glycolytic Enzymes Expression
↑ Lipogenic Gene Expression
Cell Signaling
Pathway

PI3K/Akt

→ ACL, ACC, and FAS

↓ β-oxidation

mTOR
LDH
PDK
Enzymes
ACL

↑ HIF1⍺
↑ mTOR pathway
↑ Protein Synthesis
↑ Lactate conversion from Pyruvate
↑ PDH Inactivation
↓ Pyruvate Transport into the TCA cycle
↑ Cytosolic Citrate Conversion into Acetyl-CoA
and OAA
↑Fatty Acids Synthesis

The alteration of gene expression, cell signaling pathways, and metabolic enzyme expression
cause the metabolic changes in cancer cells for efficient energy and biosynthetic mechanisms.
hypoxia-inducible factor 1 ⍺, HIF1⍺; pyruvate dehydrogenase kinase, PDK; lactate
dehydrogenase A, LDHA; phosphatidylinositol 3’ kinase, PI3K; ATP-citrate lyase, ACL; acetylCoA carboxylase, ACC; mammalian target of rapamycin, mTOR; pyruvate dehydrogenase,
PDH; oxaloacetate, OAA.
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Figure 1. Colorectal Carcinogenesis Pathways
Four stages of colorectal carcinogenesis: Initiation, Promotion, Progression, and Metastasis.
Each stage takes several years and several decades are required for all stages to be processed.
Three distinctive pathways of colorectal cancer (CRC) development.
a. Adenoma-Carcinoma Sequence accounts for 80-90% of sporadic CRC. This pathway is a
canonical pathway that normal colonocytes develop to small adenoma, to large adenoma, and to
cancer. b. Serrated pathway accounts for 10-15% of sporadic CRC. In this pathway, normal
colonocytes develop to hyperplastic polyp, to sessile serrated adenoma, and to cancer. c.
Inflammatory pathway accounts for less than 2% of sporadic CRC. Chronic inflammation
causes normal cells to develop indefinite dysplasia, to low-grade dysplasia, to high-grade
dysplasia, and to cancer.
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Figure 2. The process of genetic alteration in colorectal cancer development
The associated signaling pathways and following histological phenotype changes. At the
beginning of CRC development, mutation of the tumor suppressor APC gene triggers the
adenomatous process. Next, activation of KRAS and PI3K promote adenoma growth and
proliferation. The activation of TGF-β phosphorylates SMAD2/4, where promotes proliferation
and reduces apoptosis. The absence of TP53 increases proliferation and decreases apoptosis by
loss of DNA damage checkpoint during the cell cycle.
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Figure 3. Risk factors of colorectal cancer
The risk factors of colorectal cancer (CRC) are categorized with non-modifiable factors (age,
gender, family history, and individual history) and modifiable factors (metabolic disease,
sedentary lifestyle, smoking and alcohol consumption, and dietary factors.
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Figure 4. The physiological benefits of the metabolites derived from bacterial fermentation
and their underlying mechanism
Dietary fiber is fermented by gut microbiota producing various physiological beneficial
metabolites. SCFAs and gases, bacterial-derived metabolites, maintain colonic health, gut
microbiota homeostasis, and host energy metabolism. short-chain fatty acids, SCFAs; colorectal
cancer, CRC.
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Figure 5. Effects of host, diet, and environmental factors on the composition of gut
microbiota and its impacts of the colonic health
Several factors impact on the homeostasis of gut microbiota in the gastrointestinal (GI) tract. The
factors of the host (age, stress, genetic), environmental factors (infection, inflammation,
antibiotics and medications, and hygiene), and dietary factors (dietary fibers and red and
processed meat) can affect to the homeostasis of gut microbiota composition and their outcomes
(bacterial fermented metabolites). Dysbiosis of gut microbiota can cause immune dysregulation
and produce toxic compound and the potential carcinogenic molecules leading to unhealthy
colon status (inflammation and CRC incidence). short-chain fatty acids, SCFAs; colorectal
cancer, CRC.
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Figure 6. The different metabolism between normal colonocyte and cancerous colonocyte
Butyrate is utilized as a primary energy source in non-cancerous colonocytes by the
mitochondrial β-oxidation. In contrast, cancerous colonocytes prefer to use glucose than butyrate
as an energy source due to the Warburg effect resulting in butyrate accumulation in the nucleus.
ATP-citrate lyase, ACL; histone acetyltransferases, HATs; histone deacetylase, HDACs;
adenosine triphosphate, ATP.
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Figure 7. The butyrate synthesis pathways and the related butyrate-producing bacteria
Several bacteria produce butyrate in the gastrointestinal (GI) tract. Two final enzymes, butyrateCoA: acetate CoA-transferase (but) and butyrate kinase (buk), are alternatively utilized for the
butyrate synthesis. Butyrate-producing bacteria can be categorized into two groups according to
the enzymes that they use at the end of the pathway, either butyrate-CoA: acetate CoAtransferase (but) or butyrate kinase (buk).

49

Figure 8. Butyrate increases histone acetylation by two distinct mechanisms.
(A) Gradient concentration of butyrate through the crypts due to the mucosa flow, which is
relates to the butyrate mechanisms in histone acetylation. The higher concentration of butyrate
near the colonic lumen decreases cell proliferation and increases apoptosis as HDAC inhibitor
(ACL-independent mechanism) for the exfoliation. In contrast, the lower concentration of
butyrate near the crypt base is metabolized by mitochondrial oxidation and produce Acetyl-CoA,
which can be used as a cofactor for HATs (ACL-dependent mechanism). This mechanism
increases cell proliferation and decreases apoptosis to maintain colonic crypt homeostasis. (B)
Two distinct mechanisms of butyrate in histone acetylation depends on its concentration. At a
low level of butyrate (0.5-1mM) in colonocytes, butyrate selects ACL-dependent mechanism by
stimulating HATs. In contrast, at a high level of butyrate (2-5mM), butyrate oxidation is
saturated and the unmetabolized butyrate selects ACL-independent mechanism by inhibiting
HDACs. ATP-citrate lyase, ACL; histone-acetyltransferases, HATs; histone deacetylases,
HDACs.
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Figure 9. Biosynthetic intermediates by the metabolic shift in cancer cells
Cancer cells get lots of biosynthetic substrates from the increased glycolysis for the rapid cell
proliferation. The pentose phosphate pathway generates nucleotides for RNA and DNA
synthesis. NADPH from the pentose phosphate pathway, glycerol from DHAP, and fatty acids
from citrate of TCA cycle can be used for lipid synthesis. Serine and glycine from 3PG, aspartate
and asparagine from OAA, and glutamate, glutamine, and proline from α-KG can be utilized for
protein synthesis. nicotinamide adenine dinucleotide phosphate, NADP; ribonucleic acid, RNA;
deoxyribonucleic acid, DNA; lactate dehydrogenase A, LDHA; pyruvate dehydrogenase, PDH;
tricarboxylic acid, TCA; oxaloacetate, OAA; α-ketoglutarate, α-KG
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CHAPTER 2
PYRUVATE KINASE M1 REGULATES BUTYRATE
METABOLISM IN CANCEROUS COLONOCYTES

52

Pyruvate Kinase M1 Regulates Butyrate Metabolism in
Cancerous Colonocytes

Bohye Park1, Ji Yeon Kim1, Olivia F. Riffey2, Presley Dowker1, Antje Bruckbauer5, James
McLoughlin5, Ahmed Bettaieb1,3,4, and Dallas R. Donohoe1, 2,*

1

Department of Nutrition, University of Tennessee, Knoxville, TN 37996, USA

2

Department of Microbiology, University of Tennessee, Knoxville, TN 37996, USA

3

Graduate School of Genome Science and Technology, University of Tennessee, Knoxville, TN

37996, USA
4

Department of Biochemistry, Cellular and Molecular Biology, University of Tennessee,

Knoxville, TN 37996, USA
5

University of Tennessee Medical Center Biorepository, Knoxville, TN 37920, USA

*

Correspondence: Dallas R. Donohoe, Ph.D.
1215 W. Cumberland Ave. Knoxville, TN 37996
Office – (865) 974-6238; ddonohoe@utk.edu

Running title: PKM1 Regulates Butyrate Oxidation
Key words:
•

Butyrate

•

Glycolysis

•

PKM1

•

HIF-1alpha

•

β-oxidation

Total Number of Figures – 8 and 2 Supplemental Figures

53

2.1. Abstract
Colorectal cancer (CRC) cells shift metabolism toward aerobic glycolysis and away from
using oxidative substrates such as butyrate. Pyruvate kinase M1/2 (PKM) is an enzyme that
catalyzes the last step in glycolysis, which converts phosphoenolpyruvate to pyruvate. M1 and M2
are alternatively spliced isoforms of the Pkm gene. The PKM1 isoform promotes oxidative
metabolism, whereas PKM2 enhances aerobic glycolysis. We hypothesize that the PKM isoforms
are involved in the shift away from butyrate oxidation towards glycolysis in CRC cells. Here, we
find that PKM2 is increased and PKM1 is decreased in human colorectal carcinomas as compared
to non-cancerous tissue. To test whether PKM1/2 alter colonocyte metabolism, we created a
knockdown of PKM2 and PKM1 in CRC cells to analyze how butyrate oxidation and glycolysis
would be impacted. We report that butyrate oxidation in CRC cells is regulated by PKM1 levels,
not PKM2. Decreased butyrate oxidation observed through knockdown of PKM1 and PKM2 is
rescued through re-addition of PKM1. Diminished PKM1 lowered mitochondrial basal respiration
and decreased mitochondrial spare capacity. We demonstrate that PKM1 suppresses glycolysis
and inhibits hypoxia-inducible factor-1 alpha. These data suggest that reduced PKM1 is, in part,
responsible for increased glycolysis and diminished butyrate oxidation in CRC cells.

2.2. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States (Siegel
et al., 2020). Cancer cells primarily undergo rapid glycolysis instead of oxidative metabolism, and
this metabolic shift is associated with several critical genetic modifications (Vander Heiden et al.,
2009). Specifically, colorectal cancer cells increase glycolysis and decrease the oxidation of
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butyrate (Andriamihaja, Chaumontet, Tome, & Blachier, 2009; Donohoe, Collins, et al., 2012).
Butyrate is a short-chain fatty acid (SCFA) that is a bacterial-derived product from the
fermentation of dietary fiber (Hamer et al., 2008). Normal colonocytes use butyrate as their
primary energy source (Fleming et al., 1991; Roediger, 1982). In contrast, cancerous colonocytes
prefer to utilize glucose, and there is a concomitant diminishment in butyrate oxidation (Donohoe,
Collins, et al., 2012; Donohoe et al., 2013). The metabolic shift toward increased glucose
utilization is caused by an upregulation of enzymes that promote glycolysis in CRC (La Vecchia
& Sebastián, 2020). Therefore, it is important to understand the mechanisms that contribute to the
metabolic shift away from butyrate oxidation toward glycolysis in the cancerous colonocyte.
Much effort has been put forth to identify and characterize the genetic and environmental
factors that influence the development of CRC. The isoform of the metabolic enzyme pyruvate
kinase called PKM2 has been repeatedly identified in clinical studies as being upregulated in
colorectal cancer biopsies (Cruz et al., 2017; Kress et al., 1998; Radeva et al., 2008; Taniguchi,
Ito, et al., 2015; Yeh et al., 2008; Zhou et al., 2012). PKM2 is one of four isoforms (PKL, PKR,
and PKM1 are the others) that catalyze the final step in glycolysis, where phosphoenolpyruvate is
converted to pyruvate, and ATP is formed (Jurica et al., 1998). Importantly, each isoform has
different enzyme kinetics and a distinct function. PKM2 and PKM1 are both expressed in the colon,
however, PKM1 is generally associated with differentiated colonocytes to promote oxidative
metabolism and PKM2 is associated with proliferating and colorectal cancer cells to enhance
aerobic glycolysis (Christofk, Vander Heiden, Harris, et al., 2008; Christofk, Vander Heiden, Wu,
et al., 2008). Studies have found that elevated PKM2 expression in human cancers, including CRC,
is associated with a poor prognosis and outcome in patients (Cui & Shi, 2015). This increase in
PKM2 is so apparent that PKM2 has even been coined as a potential CRC biomarker (Cui & Shi,
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2015; Radeva et al., 2008; Yeh et al., 2008). Nevertheless, the importance of PKM2 in the
development and progression of CRC is unclear. However, given its place in the glycolytic
pathway, a metabolic role seems plausible.
In this study, experiments were conducted to distinguish the role of two different pyruvate
kinase isoforms in CRC cell metabolism. There was a particular emphasis toward characterizing
the mechanism by which PKM1/2 alters butyrate metabolism in the cancerous colonocyte. Similar
to other studies, we report that PKM2 is upregulated in CRC patient biopsies compared to the
normal colon tissues. In addition, we also find that PKM1 expression was significantly diminished
in CRC samples, suggesting a potential role of this isoform. Towards this end, we show that PKM1,
rather than PKM2, regulates butyrate oxidation in CRC cells. We further demonstrate that
diminished PKM1 causes the cell to shunt metabolism toward glycolysis away from butyrate
oxidation. This shift in metabolism is mediated through elevated hypoxia-inducible factor 1 alpha
(HIF1α), a transcription factor that promotes glycolysis. Moreover, short-chain acyl
dehydrogenase (SCAD), a necessary enzyme in the oxidation of butyrate, decreased as HIF1α
increased in CRC cells. Therefore, diminished PKM1 expression along with upregulated HIF1α
and downregulated SCAD is a key mechanism responsible for the metabolic shift in CRC cells.

2.3. Materials and Methods
Cell Culture and shRNA Transfection
The human colon cancer cell line HCT116 (ATCC, CCL-247) was grown in DMEM
supplemented with 25mM glucose and 10% FBS. PKM1 and PKM2 silencing in HCT116 was
achieved using five different hairpins (GeneCopoeia, Inc.; Rockville, MD). Lentivirus packaging
system (GeneCopoeia) was used to generate the shRNA-containing lentivirus particles in
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HEK293FT cells (GeneCopoeia) following the manufacturer’s guidelines and then used to infect
HCT116. Two scrambled non-silencing shRNA were used as controls. Cells were selected using
puromycin (2 μg/ml). For PKM1 and PKM2 overexpression, colorectal cells were infected with
EX-Lv244-mCherry-PKM1 or EX-Lv122-eGFP-PKM2 lentiviruses (GeneCopoeia) respectively,
selected using a combination of puromycin (2 μg/ml) and hygromycin (200 μg/ml), and
propagated.

Flux Experiments
To measure butyrate oxidation and mitochondrial function, Seahorse XF24 Analyzer (Seahorse
Bioscience) was used. All Seahorse assay experiments were conducted following the
manufacturer's guidelines. The % change of the oxygen consumption rates (OCR) after butyrate
injection was measured. Cells were seeded at 4.5x105/well in XF24 cell culture microplates
(Agilent Technologies, 100850). One hour before measurement, the culture medium was
replaced with 1x Krebs-Henseleit Buffer (KHB) (5mM glucose and 500 μM carnitine) for the
butyrate oxidation analysis and with Seahorse XF DMEM medium (5mM glucose, 2mM
glutamine, and 1mM pyruvate) for the mitochondrial function test, and the cell plate was
incubated in a non-CO2 incubator at 37 °C for 1hr. All Seahorse experiments were run with
identical conditions (unless otherwise noted). Briefly, for the butyrate oxidation analysis, 1x
KHB media or sodium butyrate (Sigma, B5887) at 5mM final concentration were injected, and
the change in OCR was measured from baseline (%OCR). Next, 2-deoxyglucose (2DG) 50mM
(Sigma, D8375) was injected to competitively inhibit glucose utilization and leave butyrate as
the only exogenous energy substrate. Finally, 10% sodium azide was injected to block
mitochondrial respiration by inhibiting complex IV. For the mitochondrial function test, 1x KHB
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media or sodium butyrate (Sigma, B5887) at 5mM final concentration were treated 15 mins
before measurement. Then, Oligomycin 1μM (Alfa Aesar, AAJ61898MA) was injected into the
wells to inhibit ATP synthase (complex V) following basal measurement. Next, Carbonyl
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP) 10μM (Cayman Chemical, NC0904863),
which is an uncoupling agent that collapses the proton gradient and disrupts the mitochondrial
membrane potential, was injected into the wells. At last, a mixture of rotenone 1μM (Enzo Life
Science, 03-1755), a complex I inhibitor, and antimycin A 1μM (Sigma Aldrich, A8674), a
complex III inhibitor were injected into the wells to shut down mitochondrial respiration and
calculate the nonmitochondrial respiration. After the measurements, cells were lysed with 1x
RIPA buffer (Cell Signaling, 9806s), and proteins were quantified using Pierce BCA Protein
Assay Kit (Thermo Fisher, PI23228) for normalization.

Western Blot Analysis
Proteins from cell lines were extracted with 1x RIPA buffer (Cell Signaling, 9806s),
1mM PMSF (Cell Signaling, 8553), 0.5M EDTA Solution (Thermo Scientific, R1021), and
HaltTM Phosphatase Inhibitor Cocktail (Thermo Scientific, PI87786). Samples were spun in a
centrifuge at 13,000 x g for 10 mins at 4°C, and protein supernatant was transferred to a new 1.5
ml Eppendorf tube. Protein concentrations were determined by Pierce BCA Protein Assay Kit
(Thermo Fisher, PI23228). Proteins were separated on 8 and 10% SDS-polyacrylamide gels and
transferred onto the PVDF membrane. Membranes were incubated on a rotator in 5% BSA in 1x
TBST (0.1%) for 1hr at room temperature (RT). Blocked membranes were incubated overnight
at 4°C with the respective primary antibodies on a rotator. Antibodies that were used included
PKM1 (Cell Signaling, 7067), PKM2 (Cell Signaling, 4053s), HIF1-α (Cell Signaling, 3716s),
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SCAD (Abcam, ab154823), AMPKα (Cell Signaling, 5831), phosphor-AMPKα (Thr172) (Cell
Signaling, 2535), PDH (Cell Signaling, 3205), phosphor-PDHA1 (Abcam, ab92696), and ß-actin
(Cell Signaling, 3700). Blots were washed 3 times for 10 min/wash in 1 x TBST (0.1%) at RT
and incubated with fluorescent secondary antibody for 2hr on rotator at RT following 3 times for
10 min/wash in 1x TBST (0.1%) at RT. Fluorescent detection or chemiluminescence detection of
PVDF membrane was performed with the Odyssey Fc and bands were quantified with Image
Studio Software (LI-COR Biosciences, Lincoln, NE).

Immunofluorescence staining
The clinical samples were obtained from the University of Tennessee Medical Center
Biobank with IRB# 4044. Human normal and tumor colon tissues were fixed with neutral
buffered 10% formalin for 24-36 hours, dehydrated with 70% to 100% ethanol and processed for
the production of 4-μm paraffine sections. (UTMC) Formalin-fixed paraffin-embedded tissue
sections were deparaffinized and rehydrated with xylene, ethanol, and PBS. The rehydrated
sections were blocked with 1% BSA and 5% Horse serum in PBS for 1hr at room temperature
(RT), and stained with PKM1 (Cell Signaling, 7067) and PKM2 (Cell Signaling, 4053s) primary
antibodies overnight at 4°C. Tissue sections were washed in PBS, incubated with donkey antimouse IgG (H+L) Texas Red secondary antibodies at RT for 1h, and mounted with Prolong Gold
Antifade Mountant with DAPI (Thermo Scientific, P36931) and coverslips. Tissues were
analyzed with LEICA DMi8 microscope equipped with FITC, DAPI, Texas Red, and EMP_BF
filters. All images were acquired with the same exposure and focal plane. Integrated density
(total fluorescent) per cell was quantified by the Image J (Bethesda, MD) program.
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Statistical Analysis
For seahorse experiments, western blotting, and immunofluorescence, ANOVA was used
to test for differences between experimental groups followed by a Tukey post-hoc test. All data
are expressed as mean ± SEM.

2.4. Results
PKM2 expression is increased in colorectal cancer
Several groups have reported that PKM2 is elevated in colorectal cancer samples
(Christofk, Vander Heiden, Harris, et al., 2008; Cruz et al., 2017; Cui & Shi, 2015). However, it
is unclear whether this increase in PKM2 plays any role in disease progression or outcome. In
collaboration with the University of Tennessee Medical Center Biobank, we obtained clinical
samples of colorectal cancer tissue and adjacent non-cancerous colon tissue. We performed
immunofluorescence staining on these samples to compare the different PKM isoforms in
cancerous and non-cancerous colorectal tissue. PKM2 expression was found to be increased in
colorectal carcinomas as opposed to PKM1, which was decreased when compared to adjacent noncancerous tissue (Figure 10A). In CRC tissues, PKM1 was barely detectable and showed a
significant diminishment in colorectal carcinomas (Figure 10B). These data suggest that the PKM
isoforms are differentially expressed in colorectal cancer and may allude to the functional or
metabolic importance of these proteins in the disease.

Targeting of PKM2 in colorectal cancer cells and its role in butyrate oxidation
To study the role of PKM2 in colorectal cancer cells, we targeted PKM2 with shRNA and
attempted to generate a stable knockdown cell line. Derived from the parental HCT116 colon
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carcinoma cell line, we isolated three clones (C4, C5, and C6) and analyzed the knockdown of
PKM2 by western blot. As shown in Figure 11A, PKM2 was barely detected in clone 4 (C4) and
clone 5 (C5) and was diminished in clone 6 (C6) compared to the parental HCT116 and scrambled
mock cell lines. In addition, we found that PKM1 expression in the clones differed (Figure 11A).
This was most apparent in C4, where PKM1 expression was almost abolished, and C5, which
showed overexpression of PKM1 compared to scrambled and HCT116 cells. We are not sure how
or why this happened; however, these clones provide us an opportunity to study the role of PKM1
and PKM2 in colorectal cancer cell metabolism. So, we checked the expression of Polypyrimidine
tract-binding protein 1 (PTBP1), which is one of the PKM splicer genes promoting PKM2
expression (Calabretta et al., 2016; X. He et al., 2014; Hwang et al., 2017; Xie et al., 2019).
Dysregulation of microRNA (miRNA) causes increased PTBP1 and PKM2 during carcinogenesis
(Van Roosbroeck & Calin, 2017). In addition, PTBP1 is negatively regulated by tissue-specific
miRNA (Taniguchi, Uchiyama, & Akao, 2021). Specifically, reduced miRNA, MIR1-3p,
MIR124-3p, and MIR133b, has been observed in CRC (Sugiyama et al., 2016; Taniguchi et al.,
2016; Taniguchi, Sugito, et al., 2015; Taniguchi et al., 2021). In different PKM2 knocked down
cones, we find that the level of PTBP1 is decreased in scrambled and C4, whereas PTBP1 in C5
is significantly increased (Figure 18). Furthermore, we verified whether the knockdown or
expression patterns of PKM1/PKM2 are maintained in each clone through several passages
(Figure 19). No experiments used the generated cell lines past passage 3.
Since bacterial-derived butyrate is an energetic substrate for colonocytes, and cancerous
colonocytes have been reported to show diminished oxidation of butyrate, we decided to examine
changes in butyrate oxidation in C4 and C5. The Seahorse XFe24 Extracellular Flux Analyzer,
which is an instrument that measures oxidative (oxygen consumption) and non-oxidative
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(glycolysis or lactate production) metabolism in cells was utilized to analyze butyrate oxidation in
actively respiring cells (Andriamihaja et al., 2009; Gerencser et al., 2009; Ho et al., 2012). Data
acquired with this instrument showed that butyrate oxidation was enhanced in C5 cells as
compared to the cell line expressing the scrambled mock shRNA (Figure 11B). This was in line
with diminished PKM2 expression leading to an increase in butyrate oxidation. However, when
we tested C4, we found that butyrate oxidation was significantly diminished in this clone compared
to the scramble control cells (Figure 11C). Importantly, C4 cells were able to oxidize butyrate,
however, to a lower level than scrambled cells. Subsequently, C4 and C5 both have reduced PKM2,
to a similar extent, therefore these data suggest that PKM2 diminishment is not the key factor in
regulating the oxidation of butyrate. Instead, PKM1, which was overexpressed in C5, and almost
abolished in C4, was the more likely factor in explaining these opposing results.

Rescue with PKM1 in C4 restores butyrate oxidation
To test whether PKM1 is the factor regulating differential butyrate oxidation in these
colorectal cancer cells, we re-expressed PKM1 in C4 cells to observe whether this rescued the
oxidation of butyrate to a level comparable to scrambled control cells. In addition, we re-expressed
only PKM2 in C4 cells to analyze how that would affect butyrate oxidation. In the C4 cells, PKM1
(M1R) or PKM2 (M2R) protein was increased as compared to C4 non-rescue cells (Figure 12A).
In the M1 rescue (M1R) cells, we found that the oxidation of butyrate was significantly increased
compared to C4 non-rescue cells (Figure 12B). However, expressing PKM2 in C4 cells (M2R)
showed no change in butyrate oxidation compared to C4 non-rescue cells (Figure 12C). Taken
together, these data suggested that PKM1 is largely responsible for regulating butyrate oxidation.
However, these data do not preclude a role for PKM2 in the process, but rather point to PKM1 as
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having the biggest impact on butyrate oxidation in these CRC cells. Furthermore, we confirmed
the role of PKM1 in butyrate oxidation using the HEK293 (human embryonic kidney) cell line,
which expresses PKM2, but not PKM1 (Prakasam et al., 2017). To test whether PKM1 is the major
factor regulating butyrate oxidation, we transfected PKM1 (M1R) in the HEK293 cell line, and
PKM1 was stably expressed in clone 2 (C2) cells (Figure 20A). In the C2 HEK293 cell line that
expressed PKM1, we found that the butyrate oxidation was significantly increased compared to
scramble HEK293 cells (Figure 20B). These data further support the role of PKM1 promoting
butyrate oxidation and show that PKM1 also has this effect in a non-cancerous or colorectal cell
line.
To test whether mitochondrial function, in regard to response to butyrate, is altered in C4
cells, we used oligomycin and FCCP to measure how scrambled control and C4 cells would
respond. Oligomycin is an inhibitor of ATP synthase that reduces ATP-linked oxygen
consumption, while FCCP is an uncoupling agent used to show the maximal respiratory capacity.
After injection of FCCP, butyrate caused an increased electron transport chain (ETC) accelerator
response in scramble control cells (Figure 13A). However, C4 cells, which show a large
diminishment in PKM2 and PKM1, did not show this same response. The C4 cells also showed
no response to butyrate in regard to basal respiration. This diminishment in ETC accelerator
response and basal respiration was rescued by re-addition of PKM1 in M1R cells (Figure 13B).
Also, to test whether PKM2 re-addition affects mitochondrial function response to butyrate, we
compared C4 cells and M2R cells. Here, we found that the diminishment in ETC accelerator
response and basal respiration in C4 was not rescued by re-addition of PKM2 in M2R cells (Figure
21). Thus, these data show that PKM1 is responsible for the differences in mitochondrial function
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and an overall diminishment in basal respiration in C4 cells as compared to scrambled control cells
that are rescued by PKM1 re-expression.

Molecular Consequences of diminished PKM1 and PKM2
Since C4 cells had decreased basal respiration, we next sought to test whether they also
showed an increase in the phosphorylation of AMPK (Thr172) as a proxy of energetic stress. As
expected, C4 cells showed an elevation in phospho-AMPK compared to parental HCT116 and
scrambled control cells (Figure 14A). Re-expression of PKM1 in M1R cells diminished this
activation of phospho-AMPK. Despite this activation of AMPK, one of many downstream targets,
ACC, did not show elevated phosphorylation (Figure 22).
C4 cells that also showed a significant diminishment in PKM1 and PKM2 displayed a
decrease in oxidation of butyrate, which may result in the cells shunting metabolism toward
glycolysis. In such a case, the pyruvate dehydrogenase complex (PDH) becomes inactivated
through the phosphorylation of the E1 complex member. Towards this end, C4 cells exhibited an
increase in phospho-PDH as compared to parental HCT116 cells and scrambled control cells.
However, this increase in phospho-PDH was blocked in M1R cells (Figure 14B). This suggested
that the loss of PKM1 decreases oxidative metabolism of glucose and promotes glycolysis.

Loss of PKM1 induces HIF-1alpha that decreases short-chain acyl dehydrogenase
Hypoxia-inducible factor 1 alpha (HIF1α) is a transcription factor that promotes glycolysis
in cells. Consistent with C4 cells attempting to upregulate glycolysis, HIF1α is increased. However,
re-expression of PKM1 in M1R cells reduced HIF1α back to scrambled control cell levels (Figure
15A). Based on these data and the role of pyruvate kinase in regulating the conversion of

56

phosphoenolpyruvate (PEP) to pyruvate in the glycolytic pathway, we next sought to test whether
HIF1α levels could also be reduced in C4 cells through the addition of pyruvate. Importantly, the
DMEM media we use to grow the cells and in some of the experiments lacks pyruvate. The
addition of pyruvate to the media decreased HIF1α in C4 cells as compared to scramble control
cells (Figure 15B). This alludes to the lack of pyruvate through the diminishment of PKM1 in C4
cells as the primary factor in the upregulation of HIF1α. Concomitant with the increase in HIF1α
observed in C4 cells, short-chain acyl dehydrogenase (SCAD) was found to be decreased. SCAD
mediates butyrate oxidation, and therefore any diminishment in this enzyme would result in a
decrease in butyrate oxidation. Re-expression of PKM1 in M1R cells increased SCAD levels
(Figure 16C). SCAD is the first enzyme required for short-chain fatty acids (SCFAs), including
butyrate, oxidation in the mitochondria (Bhala et al., 1995). Furthermore, when HCT116 cells
were cultured under a hypoxic condition for 24 hours to induce HIF1α, we found that SCAD levels
were significantly diminished (Figure 15D). These data suggested that loss of PKM1 in C4 cells
resulted in the cells attempting to increase glycolysis, likely through diminished pyruvate levels,
and a reduction in SCAD levels was observed in conjunction with the increase in HIF1α. An
increase in HIF1α and a decrease in SCAD may underlie lower butyrate oxidation observed in C4
cells.

Knockout of HIF1α increases butyrate oxidation in colorectal cancer cells
To test whether HIF1α plays a role in regulating butyrate oxidation, we obtained a HIF1α knockout
cell line (HIF1α -/-) (D. T. Dang et al., 2006), which was derived from a parental HCT116 cell
line. HIF1α was indeed absent in this cell line (Figure 23). In line with HIF1α, suppressing
oxidative metabolism, we found that knockout of HIF1α resulted in an increase in the oxidation of
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butyrate (Figure 16A). Moreover, CRC cells that lack HIF1α showed a diminishment in glycolysis
as judged by the decreased extracellular acidification rate (ECAR) after the addition of glucose
(Figure 16B). ECAR is used as an indirect measurement of lactate production, which is an
indication of glycolysis. Taken together, these data allude to lower PKM1 levels in stabilizing
HIF1α, which subsequently results in increased glycolysis and decreased butyrate oxidation in
CRC cells.

2.5. Discussion
The data surrounding PKM2 and colorectal cancer (CRC) is controversial. Originally, studies
seemed to show a role for PKM2 in promoting glycolysis and CRC (Sun et al., 2012; Yeh et al.,
2008; Zhou et al., 2012). However, more recent studies have found either no role for PKM2 or the
opposite result toward suppressing CRC (Y. Kim et al., 2019; Lau et al., 2017). In one study, loss
of PKM2 in colonic stem cells increased colorectal tumorigenesis in an inflammation-associated
colorectal tumor mouse model (Y. Kim et al., 2019). This would suggest that PKM2 has tumor
suppressor activity as opposed to being a proto-oncogene. Compared to PKM2, little to nothing is
known in regard to PKM1 as it relates to colorectal cancer. In a carcinogen-induced small lung
cancer mouse model, PKM1 was reported to be the main important factor in tumor growth,
development, and malignancy (Morita et al., 2018). The data presented here also support a role for
PKM1, as opposed to PKM2, in colorectal cancer. However, in contrast to PKM1 promoting small
lung cancer, our data suggest that PKM1 may play an inhibitory role in colorectal cancer as human
carcinoma biopsies showed very little PKM1 compared to non-cancerous colorectal tissue.
Colorectal cancer cells that are significantly diminished in PKM1 and PKM2 continue to
grow and proliferate, albeit slower than colorectal cancer cells that express both of these isoforms
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at full levels. As such, we found that these PKM1 and PKM2 deficient cells show a major shift in
metabolism. Going into these experiments, it was expected that PKM2 was the major isoform
promoting glycolysis, whereas PKM1 would promote oxidative metabolism. Thus, in initial
experiments, where two CRC clone cell lines both lacked PKM2 (C4 and C5), the opposing results
in terms of butyrate oxidation were surprising and provided the first hint that other factors besides
PKM2 may be important for regulating cell metabolism in regard to butyrate oxidation.
Importantly, PKM1 expression (C4 PKM1 was minimally detected by western blot, and C5 PKM1
was overexpressed) was significantly different among the clones. Thus, it became important to test
whether butyrate oxidation could be rescued through re-expressing the PKM1 isoform in the C4
cells. In fact, the addition of PKM1 increased butyrate oxidation and provided evidence that it is
an important player in the oxidation of butyrate in colorectal cancer cells. However, we cannot
exclude the involvement of PKM2 in regulating butyrate oxidation, although PKM1 appears to
have a much greater regulatory role in positively impacting this process. Moreover, it has been
suggested that butyrate oxidation is decreased in colorectal cancer cells (Donohoe et al., 2011),
which is in line with the diminished PKM1 expression in colorectal cancer biopsies. These results
also support other studies defining a function of PKM1 toward regulating and promoting oxidative
metabolism in cells (J. Han et al., 2021).
Regarding this role in regulating oxidative metabolism, PKM1, but not PKM2, has been
reported to localize to the mitochondria in H1299 and A549 lung cancer cell lines (Prakasam et
al., 2017). In addition, stable knockdown of the PKM1/2 isoforms activated AMPK in these cells,
suggesting that loss of these isoforms results in energetic stress (Prakasam et al., 2017). In the
colorectal cancer cells used in our study, it was determined that loss of both isoforms resulted in
AMPK activation, which was rescued by the re-addition of PKM1. Since colorectal cancer cells
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deficient in PKM1 and PKM2 showed reduced butyrate oxidation that was PKM1 dependent, it
was assumed that these cells would compensate, perhaps through increasing glycolysis.
Taken together, our data indicate that the diminishment of PKM1, rather than increased
PKM2, is a key factor in the metabolic shift of CRC cells by reducing oxidative metabolism and
promoting glycolysis. In our model, a diminishment in PKM1 is a mechanism to explain the
metabolic shift in CRC cells (Fig. 8). A decrease in PKM1 causes an increase in HIF1α through
reduced concentration of pyruvate, resulting in lower SCAD expression, and ultimately
suppressing butyrate oxidation and promoting glycolysis.
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Figure 10. Expression of PKM isoform in human non-cancerous and cancerous colorectal
tissues
(A) Immunofluorescence staining for PKM2 and PKM1 expression on non-cancerous colorectal
tissue and colorectal cancer tissue (B) Quantification of immunofluorescence data with relative
expression of PKM2 and PKM1 in each group. Error bars are mean ± SEM for ten independent
sections.
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Figure 11. Butyrate oxidation in PKM2 knockdown HCT116 colorectal cancer cells
(A) Western blot analysis of PKM1 and PKM2 expression in the positive control (PC; Mouse
White Adipose Tissue), HCT116, scramble (SCR), and different PKM1/2 targeted knockdown
cells with β-actin as a loading control. Quantification of the western blot is shown in the right
panel. For statistical analysis, western blot was conducted 5 times. Error bars are mean ± SEM. (B)
Percent change in oxygen consumption rate (OCR) relative to baseline in which SCR and PKM2
KD C5 cells treated with and without butyrate (5mM). Total contribution of butyrate toward OCR
(%) is observed after injection of 2-deoxyglucose (2DG). The right panel shows the area under the
curve (AUC) analysis from OCR measurements taken after 2DG injection but before azide
injection. These measurements represent butyrate oxidation (arbitrary units). (C) Percent change
in OCR relative to baseline in which SCR and PKM2 KD C4 cells treated with and without
butyrate (5mM). The right panel shows AUC analysis from OCR measurements taken after 2DG
injection but before azide injection. These measurements represent butyrate oxidation (arbitrary
units). Data points represent the average OCR (%) over 3-5 replicates per condition for butyrate
oxidation measurements. Error bars are mean ± SEM.
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Figure 12. Butyrate oxidation is PKM1 dependent rather than PKM2 in HCT116
colorectal cancer cells.
(A) Western blot analysis of PKM1 and PKM2 expressions in HCT116, SCR, and re-expressed
PKM1 (M1R) and PKM2 (M2R) cells with β-actin as a loading control. Quantification of the
western blot is shown in the right panel. For statistical analysis, western blot was conducted 5
times. (B) Percent change in oxygen consumption rate (OCR) relative to baseline in which C4 and
M1R cells treated with and without butyrate (5mM). Total contribution of butyrate toward OCR
(%) is observed after injection of 2-deoxyglucose (2DG). The right panel shows the area under the
curve (AUC) analysis from OCR measurements taken after 2DG injection but before azide
injection. These measurements represent butyrate oxidation (arbitrary units). (C) Percent change
in OCR relative to baseline in which C4 and M2R cells treated with and without butyrate (5mM).
The right panel shows the area under the curve analysis from OCR measurements taken after 2DG
injection but before azide injection. These measurements represent butyrate oxidation (arbitrary
units). Data points represent the average OCR (%) over 3-5 replicates per condition for butyrate
oxidation measurements. Error bars are mean ± SEM.
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Figure 13. PKM1 is responsible for mitochondrial function in HCT116 colorectal cancer
cells.
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in which SCR and C4
cells respond to oligomycin, FCCP, and Antimycin A/Rotenone. The right panel shows the
calculated electron transport chain (ETC) accelerator response and basal respiration. (B) Percent
change in OCR relative to baseline in which SCR and M1R cells respond to oligomycin, FCCP,
and Antimycin A/Rotenone. The right panel shows the calculated ETC accelerator response and
basal respiration. For these experiments, each cell line was treated with or without butyrate (5mM).
These measurements represent the mitochondrial function. Each data point represents the average
OCR (%) over 3-5 replicates per condition. Error bars are mean ± SEM.
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Figure 14. Molecular consequences in PKM1- and PKM2-diminished HCT116
colorectal cancer cells
(A) Western blot analysis of phospho-AMPK (Thr172) and total AMPK levels in HCT116, SCR,
C4, C5, and M1R cells with β-actin as a loading control. The right panel shows the quantification
of p-AMPK levels relative to total AMPK levels. (B) Western blot analysis of phospho-PDH
(Ser293) and total PDH levels in HCT116, SCR, C4, C5, and M1R cells with β-actin as loading
controls. The right panel shows the quantification of p-PDH levels relative to total PDH levels.
For statistical analysis, western blot was conducted 5 times. Error bars are mean ± SEM.
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Figure 15. The expression of HIF1α and SCAD is affected by PKM1.
HIF1α levels in HCT116, SCR, C4, and M1R cells with β-actin as a loading control. The right
panel shows the quantification of HIF1a expression. (B) Western blot analysis of HIF1α levels in
HCT116, SCR, and C4 cells treated with and without pyruvate (5mM). β-actin served as a loading
control. (C) Western blot analysis of SCAD levels in HCT116, SCR, C4, and M1R cells with PDH
as loading controls. (D) Western blot analysis of HIF1α and SCAD levels in HCT116 cells with
and without hypoxic conditions for 24 hours. β-actin served as loading control for HIF1α, and
PDH served as loading control for SCAD. For statistical analysis, western blot was conducted 5
times. Error bars are mean ± SEM
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Figure 16. The role of HIF1α in regulating butyrate oxidation
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in which HCT116 and
HIF1α KO cells treated with and without butyrate (5mM). Total contribution of butyrate toward
OCR (%) is observed after injection of 2-deoxyglucose (2DG). The right panel shows the area
under the curve (AUC) analysis from OCR measurements taken after 2DG injection but before
azide injection. These measurements represent butyrate oxidation (arbitrary units). Data points
represent the average OCR (%) over 3-5 replicates per condition for butyrate oxidation
measurements. (B) Percent change in extracellular acidification rate (ECAR) relative to baseline
in which HCT116 and HIF1α KO cells respond to glucose, 2DG, and azide. The right panel shows
AUC from ECAR measurements taken after glucose injection but before 2DG injection. These
measurements represent glycolysis (arbitrary units). Data points represent the average ECAR (%)
over 3-5 replicates per condition for glycolysis measurements. Error bars are mean ± SEM.
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Figure 17. Model of PKM1 regulation of cellular metabolism in cancerous colonocytes
Working model of pathways regulating butyrate oxidation. In this model, the downregulated
metabolic enzyme PKM1 is a key factor in the shift of cancerous colonocytes from oxidative
metabolism toward aerobic glycolysis. The loss of PKM1 in cancerous colonocytes leads cells to
increase glycolysis through reduction of SCAD along with an increase in HIF1α due to a decrease
in pyruvate levels. The increase in HIF1α and the decrease in SCAD together explain the lower
butyrate oxidation in CRC cells.
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Figure 18. Expression of PTBP1 in different PKM1/2 expressed cell line.
(A) Western blot analysis of PTBP1 expression with β-actin as a loading control. (B)
Quantification of the western blot. For statistical analysis, western blot was conducted 3 times.
Error bars are mean ± SEM.
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Figure 19. Confirmation of the expression of PKM1/2 in different Passage.
(A) Western blot analysis of PKM1 and PKM2 expression in different passage with β-actin as a
loading control. (B) Quantification of the western blot. For statistical analysis, western blot was
conducted 3 times. Error bars are mean ± SEM.
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Figure 20. Butyrate oxidation is PKM1 dependent in HEK293 cells.
(A) Western blot analysis of PKM1 and PKM2 expression in HEK293, SCR, and different reexpressed PKM1 clones (C2, C3, and C4) with β-actin as a loading control. Quantification of the
western blot. For statistical analysis, western blot was conducted 3 times. Error bars are mean ±
SEM. (B) Percent change in oxygen consumption rate (OCR) relative to baseline in which SCR
and C2 cells treated with and without butyrate (5mM). Total contribution of butyrate toward
OCR (%) is observed after injection of 2-deoxyglucose (2DG). The right panel shows the area
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Figure 21. Re-addition of PKM2 doesn’t impact various parameters associated with
mitochondrial function in colorectal cancer cells.
under the curve (AUC) analysis from OCR measurements taken after 2DG injection but before
azide injection. These measurements represent butyrate oxidation (arbitrary units).
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in which C4 and
M2R cells respond to oligomycin, FCCP, and Antimycin A/Rotenone. The right panel shows the
calculated electron transport chain (ETC) accelerator response and basal respiration.
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Figure 22. Relative expression of phospho-ACC/ACC in PKM1- and PKM2-diminished
HCT116 colorectal cancer cells
(A) Western blot analysis of phospho-ACC (Ser 79) and total ACC levels in HCT116, SCR, C4,
C5, and M1R cells with β-actin as a loading control. (B) Quantification of p-ACC levels relative
to total ACC levels. For statistical analysis, western blot was conducted 5 times. Error bars are
mean ± SEM.
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Figure 23. The expression of HIF1α in HCT116 cells and HIF1aKO cells
(A) Western blot analysis of HIF1α in HCT116 and HIF1α KO cells with β-actin as a loading
control. (B) Quantification of HIF1α levels relative to β-actin levels. For statistical analysis,
western blot was conducted 5 times. Error bars are mean ± SEM.
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3.1. Abstract
The host-microbiome interaction is an important component regulating colonic
health. The microbial metabolite butyrate is preferentially utilized as an energetic substrate
in colonocytes, where it mediates several beneficial functions. The composition of gut
microbiota, including butyrate-producing bacteria (BPB) is influenced by diet and
physiological conditions. As such, given the importance of butyrate as an energetic
substrate it is unclear whether the host would select for BPB, thus defining a hostmicrobiome mutualistic relationship based on cellular metabolism. Here, it is shown
through utilizing mice that lack short-chain acyl dehydrogenase (SCAD), which is the first
enzyme in the beta-oxidation pathway for SCFAs, there is a significant diminishment in
BPB at the phylum, class, species, and genus level compared to the mice that have SCAD.
Furthermore, SCAD-deficient mice lack a prebiotic response from dietary fiber. Thus,
oxidation of SCFAs, including butyrate, are important in promoting BPB. These data help
define the functional importance of diet-microbiome-host interactions toward microbiome
composition, as it relates to function.

3.2. Introduction
Trillions of microbes inhabit the gastrointestinal tract comprising a diverse and
complex ecosystem, fluctuating based on environmental factors, including diet and its
interaction with the host (Heintz & Mair, 2014). Evidence indicates that the hostmicrobiome commensal relationships and the functions of microbial-derived metabolites,
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including short-chain fatty acids (SCFAs) coming from the fermentation of dietary fiber
by specific bacteria, play a key role in the colonic health (Jha, Fouhse, Tiwari, Li, &
Willing, 2019). Metagenomic studies have demonstrated variability and individual
differences in the bacteria species in healthy and diseased populations (Adak & Khan, 2019;
Saito et al., 2019; Yachida et al., 2019). However, despite the differences, many of these
bacteria species share similar functions, such as the ability to ferment complex
polysaccharides or dietary fiber (Holscher, 2017; Turnbaugh et al., 2009). Microbiota with
the capacity to ferment fiber into SCFAs are sometimes referred to as butyrate-producing
bacteria (BPB), and variation in these bacteria between individuals provide a source of
nutritional diversity. There is an important interrelationship between butyrate-producing
bacteria and host physiology in regulating metabolic and immunological functions (Finlay,
Pettersson, Melby, & Bosch, 2019; Goldsmith & Sartor, 2014; Makki, Deehan, Walter, &
Bäckhed, 2018). How diet impacts this relationship is not entirely understood.
Firmicutes and Bacteroidetes account for more than 90% of the microbiome in the
colon (Kuo, 2013; Rinninella et al., 2019). In regard to the production of SCFAs, the
majority of BPB belong to the Firmicutes phylum (gram-negative) and mainly generate
butyrate, while the Bacteroidetes phylum (gram-positive) are characterized by producing
the other SCFAs acetate and propionate (Louis & Flint, 2009, 2017). For example,
Clostridium cluster IV and XIVa, which are generally accepted to be butyrate producers,
belong to Firmicutes phylum, and are highly oxygen-sensitive anaerobic bacteria (Guo,
Zhang, Ma, & He, 2020). The two dominant BPB species, Facalibacterium prausnitzii
within Clostridium cluster IV and Eubacterium rectale within Clostridium cluster XIVa,
are two major producers of SCFAs including butyrate (Louis & Flint, 2009, 2017). For
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butyrate production in these bacteria, two acetyl-CoA molecules form Butyryl-CoA in a
process resembling reversed butyrate oxidation. After that, two final enzymes, butyrylCoA: acetate CoA-transferase (but) and butyrate kinase (buk), are alternatively utilized to
convert butyryl-CoA to butyrate (Duncan, Barcenilla, Stewart, Pryde, & Flint, 2002).
Butyrate itself has multiple physiological functions to the host including being the
primary energy source of the colon (Nicholson et al., 2012; Roediger, 1982). In addition,
butyrate suppresses inflammation by stimulating the production and release of antiinflammatory cytokines, regulates tight junctions between colonocytes, and slows cell
proliferation in cancer cells by inhibiting histone deacetylases (Davie, 2003; Donohoe et
al., 2011; Hamer et al., 2008; Koh, De Vadder, Kovatcheva-Datchary, & Bäckhed, 2016;
Parada Venegas et al., 2019; Peng, Li, Green, Holzman, & Lin, 2009; Roediger, 1982).
Thus, the colonocyte directly, and indirectly benefits from butyrate creating a relationship
between the host and BPB. The importance of butyrate as a primary energy source for the
colonocyte and whether this impacts the microbiome, specifically BPB, provides an
interesting host-microbe selection scenario and question. Does the colonocyte, through
utilizing butyrate as a primary energetic substrate, select for, or promote BPB?
Gastrointestinal diseases such as ulcerative colitis, and colorectal cancer, which have both
been shown to have diminished butyrate oxidation, also have decreased BPB (De Preter et
al., 2012; Donohoe, Collins, et al., 2012; Machiels et al., 2014; T. Wang et al., 2012; W.
Wang et al., 2014).
The mouse BALB/cBy substrain diverged from the parental BALB/c strain
approximately 75 years ago (Gan et al., 2020). BALB/cBy mice have been reported to lack
short-chain acyl CoA dehydrogenase (SCAD), an enzyme used in the oxidation of SCFAs
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(Bhala et al., 1995). Thus, this mouse strain provides a disease-free model to test the impact
of reduced oxidation of SCFAs on the microbiome and BPB. Here, we demonstrate an
overall diminishment in the relative abundance of BPB in SCAD-deficient BALB/cBy
mice when compared to BALB/c mice. Moreover, we find that a high-fiber diet elicits a
prebiotic response in regard to BPB in BALB/c, whereas BALB/cBy mice fail to show this
same prebiotic response. Therefore, oxidation of SCFAs by the host, especially butyrate,
positively feeds back to increase the relative abundance of BPB and alter the composition
of the microbiome.

3.3. Materials and Methods
Animals
All mice in this study were obtained from The Jackson Laboratories (Bar Harbor,
ME) (BALB/c JAX #000651; BALB/cBy JAX #001026) or were bred in-house from
these stocks. All mouse experiments were performed on mice 8-10 weeks of age at 2223°C with 12hr light/dark shift. The International Animal Care and Use Committee
(IACUC) reviewed and approved animal research at the University of Tennessee,
Knoxville (Protocol #2673). All experiments were performed according to relevant
guidelines and regulations.
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Diets
Each diet was from Research Diet. The low-fiber diet (D11112201, Formula 1)
contained 2 % cellulose, whereas the high-fiber diet (D11112201, Formula 3) contained
8% inulin. BALB/c and BALB/cBy mice were fed each diet for 2 weeks.

Primary Colonocytes Isolation
Mouse colonic epithelial cells were isolated from excluding enteric neurons,
immune cells, and smooth muscle. The colons were dissected from the euthanized mice,
flushed with sterile phosphate-buffered saline (PBS), and placed in PBS solution
containing 5mM EDTA and 1% FBS. The submerged colon was incubated for ~30 min at
37°C on a rotator. The colon tissues were removed, and the left isolated colonocytes were
collected by centrifuge and used for experiments.

Flux Experiments
Seahorse XF24 Analyzer (Seahorse Bioscience, North Billerica, MA) was used to
measure butyrate oxidation and glycolysis. All Seahorse assay experiments were
conducted following the manufacturer's instructions. The % change of the oxygen
consumption rates (OCR) after butyrate injection was measured. The collected mouse
primary colonocytes were seeded in XF24 cell culture microplates (Agilent Technologies,
#100850). 1x Krebs-Henseleit Buffer (KHB) (5mM glucose and 500uM carnitine) were
used as the culture medium for the butyrate oxidation analysis. Briefly, for the butyrate
oxidation analysis, 1x KHB media or sodium butyrate (Sigma, #B5887) at 5mM final
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concentration were injected, and the change in OCR was measured from baseline
(%OCR). Next, 2-deoxyglucose (2DG) 50mM (Sigma, #D8375) was injected to
competitively inhibit glucose utilization and leave butyrate as the only exogenous energy
substrate. Finally, 10% sodium azide was injected to block mitochondrial respiration by
inhibiting complex IV. Also, for the glycolysis stress test, 1x KHB media or glucose
(Sigma, #G8270) at 10mM final concentration were injected, and the change in ECAR
was measured from baseline (%ECAR). Then, Oligomycin 2uM (Alfa Aesar,
#AAJ61898MA) was injected to inhibit ATP synthase (complex V), resulting in an
increased dependence on glycolysis following basal measurement. At last, 2deoxyglucose (2DG) 50mM (Sigma, #D8375) was injected to inhibit glucose utilization
competitively and functioned to shut down glycolysis.

Western Blot Analysis
Proteins from the collected mouse primary colonocytes were extracted with 1x
RIPA buffer (Cell Signaling, #9806s), 1mM PMSF (Cell Signaling, #8553), 0.5M EDTA
Solution (Thermo Scientific, #R1021), and Halt Phosphatase Inhibitor Cocktail (Thermo
Scientific, #PI87786). Protein samples were collected by centrifuge at 13,000 x g for 10
mins at 4°C, and protein supernatant was transferred to a new 1.5 ml Eppendorf tube.
Protein concentrations were determined by Pierce BCA Protein Assay Kit (Thermo
Fisher, #PI23228). Proteins were separated on 10 and 12% SDS-polyacrylamide gels and
transferred onto the PVDF membrane. Membranes were incubated on a rotator in 5%
BSA in 1x TBST (0.1%) for 1hr at room temperature (RT). Blocked membranes were
incubated overnight at 4°C with the respective primary antibodies on a rotator.
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Antibodies that were used included SCAD (Abcam, #ab154823), MCT1 (Abcam,
#ab179832), AMPKα (Cell Signaling, #5831), pAMPKα (Cell Signaling, #2535s), ACC
(Cell Signaling, #3676s), pACC (Cell Signaling, #11818s), and ß-actin (Cell Signaling,
#3700). Blots were washed 3 times for 10 min/wash in 1 x TBST (0.1%) at RT and
incubated with secondary antibody for 2hr on rotator at RT following 3 times for 10
min/wash in 1x TBST (0.1%) at RT. Fluorescent or chemiluminescence detection was
performed with the Odyssey Fc, and bands were quantified with Image Studio Software
(LI-COR Biosciences, Lincoln, NE).

Microbial DNA preparation and Quantitative Real-Time PCR Analysis
Microbial DNA was isolated from the collected feces, dissected cecum, colon,
and flushed feces from the dissected colon. Total bacterial DNA was isolated using
DNeasy PowerSoil Pro Kit (QIAGEN Sciences Inc. Germantown, MD) according to the
manufacturer’s instructions. Total DNA was quantified using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE). About 100ng of DNA
from each sample was used to analyze the bacterial population. Primers for quantifying
specific bacterial groups and the butyrate kinase (buk) and butyryl-CoA:acetate CoAtransferase (but) gene are given in Supplemental Table1. Targeted DNA expression was
measured quantitatively using the Power Up SYBR master mix (Life technologies,
#A25742). Thermocycling was done as follows; 2min at 95°C; 45s at 95°C, 45s at 54°C,
45s at 72°C (x35); 10min at 72°C.
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Statistical Analysis
For seahorse experiments, western blotting, and qPCR, an ANOVA was used to
test for differences between experimental groups followed by a Tukey post-hoc test. All
data are expressed as mean ± SEM.

3.4. RESULTS
Characterization of BALB/cBy colonocytes and their reduced butyrate oxidation
Colonocytes were isolated from BALB/c and BALB/cBy mice and the expression
of SCAD was analyzed by western blot. As shown in Figure 24A, the levels of SCAD
were significantly diminished, but they were not completely abolished as we still could
detect the protein. Since BALB/cBy mice are deficient in SCAD, the relative levels of
monocarboxylate transporter 1 (MCT1), a major butyrate transporter, were measured in
comparison to BALB/c to assess whether SCAD-deficient colonocytes increased MCT1 as
a compensatory mechanism (Figure 24A). However, the levels of MCT1 did not show a
significant change in BALB/cBy colonocytes. AMP kinase (AMPK) is a proxy for cellular
energetics, as phosphorylation of this protein at Thr172 occurs under energetic stress or
deprivation (Herzig & Shaw, 2018). Phosphorylation of AMPK (Thr172) was significantly
higher in SCAD-deficient (BALB/cBy) compared to non-deficient (BALB/c) colonocytes
(Figure 24B). Thus, it is likely that the diminishment in SCAD results in decreased
butyrate oxidation and energetic stress in the colonocyte. Furthermore, SCAD-deficient
colonocytes showed increased phosphorylation and thus inactivation of Acetyl-CoA
Carboxylase (ACC), which is also a downstream target of AMPK (Figure 24C).
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Inactivation of ACC would increase fatty acid transport via carnitine palmityl transferase
(CPT) as a result of reduced malonyl-CoA levels (Lipovka & Konhilas, 2015). However,
given the diminishment in SCAD, which is located in the mitochondria, and is the first step
in the beta-oxidation process for SCFAs, it is unlikely that inactivation of ACC would have
a significant impact on the oxidation of butyrate.
The Seahorse XFe24 Extracellular Flux Analyzer, which measures oxidative
(oxygen consumption) and non-oxidative (lactate production or glycolysis) metabolism in
cells, was utilized to test whether reduced levels of SCAD in the colonocytes resulted in
decreased butyrate oxidation (Andriamihaja et al., 2009; Gerencser et al., 2009). Isolated
colonocytes derived from SCAD-deficient mice did not respond to butyrate as judged by
the change in their oxygen consumption rate after injection butyrate or 2-deoxyglucose
(2DG), which is used to block glucose oxidation leaving butyrate as the only exogenous
energy source for the colonocyte (Figure 25A). In fact, the oxygen consumption rate in the
butyrate 5mM treated BALB/cBy group was almost identical to the control group that had
no butyrate. If butyrate, which is the primary energy source of colonocytes, is abolished,
then the colonocyte may compensate through increasing glycolysis. This was indeed the
case as SCAD-deficient colonocytes displayed elevated glycolysis as judged by the
increased extracellular acidification rate (ECAR) after the addition of glucose (Figure
25B). The ECAR measurement represents an indirect measurement of lactate secretion and
glycolysis. Taken together, these data demonstrate that diminishment in SCAD impacts
cellular metabolism by reducing butyrate oxidation and increasing glycolysis in the
primary isolated colonocytes.
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Analyzing the Butyrate Synthesis Enzyme as a Biomarker of Butyrate-Producing
Bacteria in BALB/c and BALB/cBy
A gene-targeted quantitative polymerase chain reaction (qPCR) was utilized to analyze
butyrate-producing bacteria (BPB) in BALB/c and BALB/cBy mice. The two final
enzymes in the bacterial butyrate synthesis pathways, butyryl-CoA:acetate CoAtransferase (but) and butyrate kinase (buk), were targeted for amplification and each
represented a biomarker for relative BPB amounts. A qPCR for total 16S was used to
analyze but or buk relative to total bacteria. Initially, degenerative primers designed by
Louis and Flint (2003, 2007) were utilized for but and buk genes, but these PCR reactions
yielded several unexpected bands, which precluded their use in qPCR. From the but and
buk PCR reactions, the expected amplicons were sequenced, and several new primers were
designed and tested. Importantly, PCR reactions with these new primers gave the expected
amplicon, while having no non-specific bands. The process to get the specific buk primer
from the degenerative primers is explained in Figure 30A.
Comparison of but and buk between BALB/c and SCAD-deficient BALB/cBy mice
from collected individual fecal pellets yielded significant variability, even following the
same mouse day-to-day (Figure 30B and C). The pH conditions in the colon can have a
significant impact on microbial survival, and there is an increase in pH moving from the
proximal to the distal part of the colon (Macfarlane, Gibson, & Cummings, 1992; Nugent,
Kumar, Rampton, & Evans, 2001). Dietary fibers are fermented by intestinal microbes to
produce SCFAs, which lower the pH in the proximal colon (Walker et al., 2005). The more
acidic conditions in the proximal colon favor the growth of BPB. Thus, it was not clear
whether the variability was an inherent part of the BPB or was due to where and how we
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collected samples. Taking a more location-centric approach, such as taking feces directly
from the colon would maybe decrease variability in our samples. Thus, a new experimental
approach was used to collect bacterial DNA (Figure 26A). The bacterial DNA was isolated
from the dissected cecum, colon, and feces from the sacrificed mice. Cecum was also used
because it is the primary site of fermentation in mice (K. Brown, Abbott, Uwiera, & Inglis,
2018). With this experimental approach, the variability was diminished, and the amount of
both butyrate synthesis enzymes (but and buk) were significantly decreased in bacterial
DNA samples of the cecum, colon, and feces in SCAD-deficient BALB/cBy mice
compared to BALB/c mice (Figure 26B and C). These data demonstrate deficient SCFAs
and butyrate oxidation in the host results in a decrease in the BPB population.

Diminished Butyrate-Producing Bacteria in SCAD mutant BALB/cBy Mice
To compare the abundance of specific butyrate-producing bacteria (BPB) populations, we
investigated BPB from phylum to species level with collected bacterial DNA samples
isolated from the dissected cecum, colon, and feces of BALB/c and BALB/cBy mice using
qPCR. Sequence information for the primers of specific bacterial groups is given in Table
3. At the phylum level, the amount of Firmicutes in the cecum, colon, and feces of SCADdeficient BALB/cBy mice was significantly decreased compared to those in BALB/c mice
(Figure 27A). However, the relative amount of Bacteroidetes, which are mainly nonbutyrate-producing bacteria (non-BPB), showed an opposite trend of being slightly
increased in BALB/cBy, although only reaching a significant difference in the colon
(Figure 27B). Looking at the class cluster level, the amount of Clostridium IV and XIVa,
known butyrate-producers (Louis & Flint, 2009, 2017), were significantly diminished in
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BALB/cBy compared to BALB/c mice when analyzing the cecum, colon, and feces
(Figure 27C and D). At the species level, the amount of Facalibacterium prausnitzii and
Eubacterium rectale at each location decreased in BALB/cBy mice compared to BALB/c
mice (Figure 27E and F). However, Facalibacterium prausnitzii was not detected at all in
the fecal samples, which suggests that location and collection method is particularly
important for detecting bacteria. These data demonstrate, in this non-disease model, that
decreased butyrate and SCFAs oxidation of SCAD-deficient mice is associated with a
significant diminishment in BPB, thereby defining an important relationship between host
cellular metabolism and the gut microbiota as it pertains to BPB.

Butyrate-Producing Bacteria Responded in a High-Fiber Diet in Wild Type Mice
Fermentable dietary fiber contributes to an increased butyrate-producing bacteria (BPB)
population, associated with less inflammation and inflammatory disease development
(Carding et al., 2015) Differences in the prebiotic effect derived from fiber have been
observed, where selective individuals don’t increase BPB (Deschasaux et al., 2018; G.
Falony et al., 2016; J. Li et al., 2014; Murga-Garrido et al., 2021).
Since SCAD-deficient BALB/cBy mice showed a diminishment in BPB as
compared to BALB/c mice on a standard chow diet, a defined low-fiber diet (LFD) and
high-fiber diet (HFD) were used to test whether BALB/cBy mice would show a prebiotic
effect represented by an increase in BPB from low-fiber to high fiber diet. To study how
dietary fibers affect BPB, BALB/c and BALB/cBy mice were randomly divided into four
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groups based on diet. They were fed a calorically matched LFD with cellulose and HFD
with inulin to analyze the effects of diet on relative BPB levels.
The level of but and buk in BALB/c mice increased from LFD to HFD conditions,
however, SCAD-deficient BALB/cBy mice showed no difference (Figure 28A and B). A
similar result was found in analyzing Eubacterium rectale and Facalibacterium Prusnitzii
where both were increased in the HFD condition of BALB/c mice, but there was no
response in BALB/cBy mice in HFD compared to LFD group (Figure 28C and D).
Furthermore, in conditions of low butyrate production and levels, there were no differences
in the LFD groups between BALB/c and BALB/cBy when analyzing but and buk or the
species Eubacterium rectale and Facalibacterium Prusnitzii (Figure 28). These data are
consistent with the idea that reduced butyrate oxidation in SCAD mutant colonocytes
causes a decrease in the amount of BPB even with enough fermentable substrates.

3.5. DISCUSSION
The gastrointestinal (GI) tract is a complex ecosystem in which host intestinal epithelium,
immune cells, and gut microbiota live in symbiotic relationships (Bäckhed, Ley,
Sonnenburg, Peterson, & Gordon, 2005). Changes in the GI tract environment, including
dietary fiber, antibiotics, hygiene, and host physiology, can re-shape the gut microbiota
community and is associated with diseases such as inflammatory bowel diseases (IBDs) or
colorectal cancer (CRC) (Holmes et al., 2011; Kinross et al., 2011; Sommer & Bäckhed,
2013). The loss of gut microbiota diversity and decreased butyrate oxidation are major
characteristics of CRC patients (Donohoe, Collins, et al., 2012; T. Wang et al., 2012).
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However, the causative mechanism has not been well understood yet as to how or what
drives gut microbial dysbiosis in colon disease patients compared to healthy controls. In
this study, we report that diminished butyrate and SCFA oxidation results in decreased
butyrate-producing bacteria (BPB) levels in a non-disease SCAD-deficient mouse model.
SCAD-deficient mouse colonocytes show a decrease in butyrate oxidation and an
increase in glycolysis. Similarly, colonocytes transforming to become cancerous display
this same metabolic shift called the Warburg effect (Andriamihaja et al., 2009; Donohoe,
Collins, et al., 2012). Although these metabolic patterns are similar between SCADdeficient colonocytes and cancerous colonocytes, it is likely that the reason for the increase
in glycolysis is not because of the Warburg effect in SCAD-deficient colonocytes, but
rather because they can obtain energy from glycolysis as a compensatory mechanism. This
is supported through the fact that AMPK is activated in the SCAD-deficient colonocytes.
The decreased level of butyrate-producing bacteria is another feature in CRC
patients where SCAD reduction is observed (Ferreira-Halder, Faria, & Andrade, 2017; A.
Han, Bennett, Ahmed, Whelan, & Donohoe, 2018; Miquel et al., 2013; Sobhani et al.,
2011). Figure 26 and Figure 27 show that the level of butyrate-producing bacteria is
significantly diminished in the cecum, colon, and feces of SCAD-deficient mice compared
to the wild-type mice. These data would suggest that decreased butyrate oxidation in nondisease SCAD-deficient mice leads to a decrease in the population of butyrate-producing
bacteria.
Butyrate-producing bacteria are anaerobic bacteria, and the low oxygen levels in
the GI tract provide them with a favorable environment (Parada Venegas et al., 2019). In
addition, the butyrate oxidation consumes considerable oxygen in the host colonocyte,
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thereby making hypoxic conditions (<1% O2 or <7.6 mmHg) (Colgan & Taylor, 2010;
Kelly et al., 2015). However, going into our data, the reduction of SCAD in the BALB/cBy
mice colonocyte decreased butyrate oxidation, thereby we can predict conserving and
increasing the oxygen level within the colonocyte. Since oxygen diffuses freely across
epithelial membranes, the elevated oxygen concentration in the colonocytes can drive an
increased oxygen availability in the intestinal lumen. The aerobic environment in the
gastrointestinal tract could deplete butyrate-producing bacteria and drive a pathogen
expansion (Espey, 2013; Rivera-Chávez et al., 2016).
Different types of diets affect the composition of gut microbiota, which could affect
the production of microbial-derived metabolites, including butyrate (Makki et al., 2018;
Scott et al., 2013; Tan et al., 2014). Particularly, fermentable dietary fiber contributes to an
increased butyrate-producing bacteria population, associated with less inflammation and
inflammatory disease development (Carding et al., 2015). Among the various dietary fiber
groups in our study, it was determined that the level of butyrate-producing bacteria in wildtype mice increased in response to the high-fermentable dietary fiber, while its level in
SCAD-deficient mice did not respond under the same condition (Figure 28). These results
support the functional importance of diet-microbiome-host interactions toward host colon
health.
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Figure 24. Molecular consequences in short-chain acyl dehydrogenase (SCAD)
mutant mouse colonocytes
(A) Western blot analysis of short-chain acyl dehydrogenase (SCAD) and
monocarboxylate transporter 1 (MCT1) levels in the isolated colonocytes from BALB/c
and BALB/cBy mice with β-actin as a loading control. Quantification of the western blot
is shown in the right panel. For statistical analysis, western blot was conducted 5 times.
Error bars are mean ± SEM. (B) Western blot analysis of phospho-AMPK (Thr172) and
total AMPK levels in the isolated colonocytes from BALB/c and BALB/cBy mice with βactin as a loading control. The right panel shows the quantification of p-AMPK levels
relative to total AMPK levels. (C) Western blot analysis of phospho-ACC (Ser 79) and
total ACC levels in the isolated colonocytes from BALB/c and BALB/cBy mice with βactin as a loading control. The right panel shows the quantification of p-ACC levels relative
to total ACC levels. For statistical analysis, western blot was conducted 5 times. Error bars
are mean ± SEM.
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Figure 25. SCAD mutant mice prefer glucose rather than butyrate as an energy source
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in which
isolated colonocytes from BALB/c and BALB/cBy mice treated with and without butyrate
(5mM). Total contribution of butyrate toward OCR (%) is observed after injection of 2deoxyglucose (2DG). The right panel shows the area under the curve (AUC) analysis from
OCR measurements taken after 2DG injection but before azide injection. These
measurements represent butyrate oxidation (arbitrary units). Data points represent the
average OCR (%) over 3-5 replicates per condition for butyrate oxidation measurements.
Error bars are mean ± SEM. (B) Percent change in extracellular acidification rate (ECAR)
relative to baseline in which isolated colonocytes from BALB/c and BALB/cBy mice
respond to glucose, 2DG, and azide. The right panel shows AUC from ECAR
measurements taken after glucose injection but before 2DG injection. These measurements
represent glycolysis (arbitrary units). Data points represent the average ECAR (%) over 35 replicates per condition for glycolysis measurements. Error bars are mean ± SEM.
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Figure 26. Analysis of the level of butyrate synthesis enzyme as a biomarker of
butyrate-producing bacteria (BPB)
(A) The diagram shows the locations where microbial DNA samples were collected. (B)
and (C) Quantification of butyrate kinase (buk) and the level of butyrate synthesis
enzyme butyryl-CoA: acetate CoA-transferase (but) in different gut locations and feces of
BALB/c and BALB/cBy mice relative to 16S rRNA. Error bars are mean ± SEM.
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Figure 27. Exploring the butyrate-producing bacteria (BPB) community based on
qPCR analysis
(A) Quantification of the level of Firmicutes in different gut locations and feces of BALB/c
and BALB/cBy mice relative to 16S. (B) Quantification of the level of Bacteroidetes in
different gut locations and feces of BALB/c and BALB/cBy mice relative to 16S. (C)
Quantification of the level of Clostridium XIVa in different gut locations and feces of
BALB/c and BALB/cBy mice relative to 16S. (D) Quantification of the level of
Clostridium IV in different gut locations and feces of BALB/c and BALB/cBy mice
relative to 16S. (E) Quantification of the level of Eubacterium rectale in different gut
locations and feces of BALB/c and BALB/cBy mice relative to 16S. (F) Quantification of
the level of Faecalibacterium prausnitzii in different gut locations and feces of BALB/c
and BALB/cBy mice relative to 16S rRNA. For statistical analysis, qPCR was conducted
three times per condition. Error bars are mean ± SEM.
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Figure 28. Impact of different dietary fiber diets on the composition of
butyrate-producing bacteria
BALB/c and BALB/cBy mice were fed the low-fiber diet contained 2 % cellulose, or the
high-fiber diet contained 8% inulin for 2 weeks. (A) Quantification of the level of butyrate
kinase (buk) in different gut locations and feces of BALB/c and BALB/cBy mice in each
diet group relative to 16S. (B) Quantification of the level of butyryl-CoA: acetate CoAtransferase (but) in different gut locations and feces of BALB/c and BALB/cBy mice in
each diet group relative to 16S. (C) Quantification of the level of Eubacterium rectale in
different gut locations and feces of BALB/c and BALB/cBy mice in each diet group
relative to 16S. (D) Quantification of the level of Faecalibacterium prausnitzii in different
gut locations and feces of BALB/c and BALB/cBy mice in each diet group relative to 16S
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rRNA. For statistical analysis, qPCR was conducted three times per condition. Error bars
are mean ± SEM.
Primer
1132_F

Target
16s

1108_R
ButyrateKinase_F
ButyrateKinase_R
ButyrateTransferase_
F
ButyrateTransferase_
R
Firmicutes_F

ClostridiumXIVa_R
ClostridiumIV_F

Butyrate
Kinase
Butyrate
Transferase

Bacteroidetes_R
Eubacterium
Rectale_F
Eubacterium
Rectale_R
Faecalibacterium
Prausnitzii_F
Faecalibacterium
Prausnitzii_R

CAATCGTGGACCAGAAGGATTT
ACCGATGGAATCAGCAATTTCCCG
GCIGAICATTTCACITGGAAYWSITGGCAY
ATG
CCTGCCTTTGCAATRTCIACRAANGC

Firmicutes

GGAGYATGTGGTTTAATTCGAAGCA
AGCTGACGACAACCATGCAC

Clostridium
XIVa
Clostridium IV

ClostridiumIV_R
Bacteroidetes_F

ATGGYTGTCGTCAGCTCGTG
GGGTTGCGCTCGTTGC

Firmicutes_R
ClostridiumXIVa_F

Sequence (5' - 3')

CGGTACCTGACTAAGAAGC
AGTTTYATTCTTGCGAACG
TTACTGGGTGTAAAGGG
TAGAGTGCTCTTGCGTA

Bacteroidetes

GAAGGTCCCCCACATTG
CAATCGGAGTTCTTCGTG

Eubacterium
Rectale

GCGGTRCGGCAAGTCTGA

CCTCCGACACTCTAGTMCGAC
Faecalibacteriu
m Prausnitzii

GATGGCCTCGCGTCCGATTAG
CCGAAGACCTTCTTCCTC

Table 3. Primer Sequences used in this study
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Figure 29. Experimental model for collected fecal samples for 16S rRNA and 1PCR
analysis
Bacterial DNA was extracted from the individually collected fecal samples for the 16S
rRNA sequencing and qPCR.
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(A) The process of generating a specific butyrate kinase (buk) primer from the
degenerative primer. (B) Quantification of the level of butyrate kinase (buk) and butyrylCoA: acetate CoA-transferase (but) in the collected fecal samples. (C) Quantification of
the level of butyrate kinase (buk) in the collected fecal samples with the day-to-day
experiment. For statistical analysis, qPCR was conducted three times per condition. Error
bars are mean ± SEM.
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Figure 31. Impact of different dietary fiber diets on the composition of butyrateproducing bacteria in the small intestine of BALB/c and BALB/cBy
(A) Quantification of the level of butyrate kinase (buk) and butyryl-CoA: acetate CoAtransferase (but) in the small intestine of BALB/c and BALB/cBy mice in each diet group
relative to 16S rRNA. (B) Quantification of the level of Clostridium XIVa and
Clostridium IV in the small intestine of BALB/c and BALB/cBy mice in each diet group
relative to 16S rRNA. For statistical analysis, qPCR was conducted three times per
condition. Error bars are mean ± SEM.
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CONCLUSION AND FUTURE DIRECTION
In this dissertation, it has been reported that (1) butyrate oxidation in cancerous
colonocytes is regulated by PKM1, not by PKM2; (2) the reduced PKM1 in cancerous
colonocytes lowered mitochondrial functions; (3) a decrease in PKM1 causes an increase
in HIF1α, through a reduction of pyruvate, thereby lowers SCAD expression, suppressing
butyrate oxidation and promoting glycolysis; (4) butyrate oxidation was significantly
lowered in SCAD mutant non-disease mice model (5) the butyrate-producing bacteria
(|BPB) population was significantly reduced in SCAD mutant mice (6) SCAD-deficient
mice fail to respond the fermentable fiber in a high-fiber diet condition.
Our findings suggest a better understanding of butyrate metabolism and the
different roles of PKM isoforms in cancerous colonocytes. Moreover, we explain how
colonocyte metabolism affects the BPB composition in the host colon. This may suggest
an even more profound aspect. If the colonocytes no longer utilize butyrate to its benefit
as an energy source, it may not promote or select for bacteria that produce it.
In the future, based on the results of in vitro models suggested in chapter 2,
research on the role of PKM isoforms in the development and progression of colorectal
tumors would be necessary by using animal models. Successful animal studies will
explore the impacts of PKM isoforms during colorectal tumor initiation, development,
and progression into a carcinoma. Moreover, based on the findings of chapter 3, we need
to study how the host-microbiome relationship affects colon disease development, such
as IBDs and CRC. These future studies will illustrate the importance of a hostmicrobiome relationship in establishing the gastrointestinal microbiome and would help
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explain the reason why certain colon diseases show diminished butyrate oxidation have
decreased BPB.
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